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Abstract
The protozoan blood-borne parasite Trypanosoma cruzi is the causative agent of 
Chagas’ disease, an enervating and often fatal illness prevalent in South and Central 
America for which there is no effective treatment. T. cruzi has a cell-surface trans- 
sialidase which transfers sialic acid from mammalian oligosaccharides to the 
parasite. This action allows adhesion to and invasion of mammalian cells, 
subsequently allowing parasitic replication. Tliis protein therefore is exploitable and 
represents a potential target for the development of chemotherapeutic agents. This 
thesis describes the purification of recombinant trans-smXiàsiSQ and the development 
of a rapid, reliable spectrophotometric coupled assay to measure /ra«^-sialidase 
activity. It also details the use of three mutually exclusive synthetic oligosaccharide 
libraries to map substrate recognition for the enzyme. Synthetic fragments of the 
natural branched oligosaccharide substrates have also been sialylated on a 
preparative scale, demonstrating the use of r^a«.S“Sialidase in synthetic 
oligosaccharide chemistry.
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Chagoma Biological swelling as a result of T. cruzi
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GalNAc A-Acety Igalacto samine
Glc Glucose
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High performance liquid chromatography
50 % inhibition concentration
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Chapter 1
Introduction
1.1 Chagas’ Disease
The parasite Trypanosoma cruzi is the causative agent of Chagas’ disease, a 
debilitating condition discovered in 1909 in Brazil by Carlos Chagas. This disease is 
already endemic in Latin America, affecting approximately 8 % of the population of 
South and Central America as indicated in Figure 1 {Colli 1993, Muller and Baker 
1990). This number is only an estimation since difficult geography and inadequate 
reporting may underestimate the numbers exposed.
Figure 1 Incidence of Chagas’ disease in South and Central America 
(Highlighted in black) Muller and Baker 1990
The migration of population from Latin America to the United States to escape poor 
housing and living conditions has highlighted this disease {Kirchhoff et al 1997). 
Blood studies carried out in the southern most States of North America (i.e. 
California and Florida) assessed the potential risk of the spread of disease.
1.1.2 Blood studies
Population migration is often a problem for both health organisations and 
governments trying to prevent spread of disease {Kirchhoff et al 1997). The Food 
and Drug Administration (FDA), American Association of Blood Banks Standards 
(AABBS) and the American Red Cross (ARC) carried out their own investigations, 
from June 1993-1995, screening blood from blood donors in the US for anti T. cruzi 
antibodies. The tests showed that 3-4 % of the blood donors that had lived m an 
endemic area, in poor housing, or had received a blood transfusion in that country had 
specific antibodies to T. cruzi {i.e. that they had been in contact with the disease) 
{Kirchhoff et al 1997). However, no one born in the US had antibodies to T. cruzi. 
This indicates that frequent travellers to a Chagas’ disease endemic country are at 
little risk provided they do not live there or receive a blood transfusion there 
{Kirchhoff et al 1997). All blood transfusion samples are now routinely screened 
with the (commercially available) immunoassays used in these studies. In the USA, 
FDA research indicates that there has been only one reported case of blood with 
possible T. cruzi antibodies present being transfused (discovered retrospectively but 
with no sign of infection). Similarly, ARC studies uncovered 11 possible recipients of 
contaminated blood but with no trace of disease {Kirchhoff et al 1997).
A similar volimtary study was carried out on a group of one hundred Latin 
American immigrants (60 men 40 women) living in Berlin, Germany, between May 
and August 1995 {Frank et al 1997). This study assessed the conceivable risk of 
infection of T. cruzi in congenital transmission and blood transfusion, previously 
cautioned by the World Health Organisation (WHO). An indirect 
immunofluorescence assay (IIF) using antigenic immobilised trypomastigotes 
(parasites) was used to test aft subjects. A control group of non-Latin American 
Germans was also tested. The positive IIF samples were subsequently assessed by 
ELISA using crude Peruvian T. cruzi strain. Only five of the 100 samples tested 
positive to both tests {Frank et al 1997). To exclude any potentiality of cross­
reactivity, the group was also tested with Leishmania infantum antigens. All samples, 
which gave positive tests with Leishmania infantum, were excluded from the study. 
Five subjects tested positive to IIF/ELISA but only two (one male, one female) were
negative to the Leishmania assay also. These two individuals were from Urban South 
America, although it is believed that Chagas’ disease is more prevalent in rural areas 
{Frank et al 1997). Hence, the relative existence of T. cruzi in this sample of South 
American immigrants is 2 %. The estimation of the risk of blood infection fr-om T. 
cruzi by the WHO is 4 to 5 % {Frank et al 1997). Blood transfusion in Brazil is 
believed to be responsible for 20 % of the 100,000 new cases of T. cruzi each year, 
with a 13-25 % risk of infection with each unit of blood transfused {Frank et al 
1997). It is thought that the number of immigrants fr*om South and Central America 
now living in Europe is approximately 300,000 hence, the WHO estimates that there 
are 15,000 T. cruzi carriers in Europe {Frank et al 1997).
1.1.3 The Disease and its effects
Chagas’ disease has two forms: chronic and acute {Muller and Baker 1990). The 
acute form lasts for only a few months, with T. cruzi replicating very quickly in the 
host causing death. In the chronic form, the patient may not develop any symptoms 
for many years (approximately eight). After infecting the host, the parasite remains 
dormant {Muller and Baker 1990). The initial incubation time for the disease can be 
up to a few weeks with only one in four patients developing the disease {Kirchhoff et 
al 1997). Hence, life expectancy and symptoms of sufferers are very varied {Muller 
and Baker 1990, Smyth 1994): only immuno-compromised patients {i.e. HIV 
patients) exhibit all symptoms early on in the sickness {Kirchhoff et al 1997).
On contracting the disease, the parasite re-sites in the blood stream where it 
removes sialic acid from soluble and human cell surface glycoconjugates. Neurones 
are particularly vulnerable {Muller and Baker 1990). Pseudo cysts released by the 
parasite are mainly concentrated in the gastrointestinal tract, oesophagus, colon or the 
heart. The resultant enlargement of tissue, causing considerable distress and 
discomfort is known as a Chagoma {Smyth 1990 and Muller and Baker 1990).
Swelling of the colon can lead to rupture of the stomach, whereas 
oesophageal swelling causes starvation. However, the most common fatal condition 
is pseudo cyst aggregation in the heart and denervation, causing permanent cardiac 
damage and heart failure. “Swollen eyes” are also a classic symptom of an infected 
patient {Smyth 1990).
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1.1.4 Host resistance to ^m«5-sialidase
The macrophage is the principal resistance mechanism shown in both in vitro and in 
vivo experimental studies to the T. cruzi pathogen {Gazzinelli et al 1997). The IFN-y 
macrophage is produced in the resphatory tract in response to the pathogen, wliich in 
turn liberates reactive oxygen species to destroy the parasite {Gazzinelli et al 1997). 
The microbiocidal activity against T, cruzi displayed by murine macrophages is largely 
because of oxygen-independent nitric oxide synthesis. This hypothesis has been tested 
with nitric oxide synthesis inducing compounds and with mui ine macrophages which 
show increased anti-parasitic activity {Gazzinelli et al 1997).
1.1.5 Possible treatments
Currently there is no known cure or effective treatment for Chagas’ disease. The 
nitrogen heterocycles nifurtimox and benznidazole are commonly used, but have little 
effect and only early on in the sickness. Both are toxic to the patients {Muller and 
Baker 1990). The structuie of these drugs is shown below in Figure 2.
Figure 2 Structure of nifurtimox and benznidazole
CH3
Nifurtimox Benznidazole
Trypanosomes, like mammals, use reduced glutathione (GSH) to prevent possible 
damage by free radicals {Cassels et al 1995). However they lack the essential enzyme 
glutathione reductase (GR), and consequently use a non-enzymatic process involving 
trypanothione (T[SH]2) to produce GSH {Cassels et al 1995). Trypanothione 
reductase (TR) maintains the correct level of GSH required. TR and GR are 
completely distinct, are non-interchangeable and can therefore be exploited as 
potential drug targets. Interestingly, nifrntimox, used as a trypanothione reductase
inhibitor, is a better inhibitor of GR than TR, which explains some of the highly toxic 
effects exhibited by patients {Cassels et al 1995). The ability to inhibit one enzyme 
selectively is an essential commodity of any possible compound used as a drug. Many 
such compounds have been identified but other criteria such as poor solubility or low 
potency have limited their uses.
1.2 Trypanosoma cruzi
Trypanosoma cruzi is an elongated protozoon of between 15-25 gm in length, with a 
curved flagella, shown in Figure 3. It does not have a surface coat and cannot 
undergo any antigen variation, in contrast to its African counterpart T. hrucei 
{Ferguson et al 1994). To avoid detection by the hosts immune system the parasite 
quickly moves out of the bloodstream into cells {Smyth 1994).
Figure 3 Photograph of Trypanosoma cruzi (1000 x magnification)
1.2.2 T. cruzi transmission vector
The T. cruzi transmission vector is the brightly coloured reduvid beetle, shown below 
in Figure 4A. In this vector, the parasite is restricted to the gut. The beetle uses a 
proboscis located anterior to puncture the hosts’ skin to gain access to the blood 
stream {Colli 1993). After ingestion of a blood meal, the beetle immediately defecates 
on the surface of the hosts’ skin. The beetle puncturing the hosts’ skin causes an 
irritation and the inevitable scratching. The parasite then gains entry to the 
bloodstream via the faeces (or in some cases via mucus membranes). A photograph of 
the faeces is shown below in Figure 4B.
Figure 4 Photograph of the reduvid beetle {Triatoma infestans) A and 
faeces (amastigote) B
http://vflylab.angis.org.au/edesktop/WWW_Projects/Animals_Plants/TrypanosomaCr 
uzithuynh/Start. html
Triatoma infestans
A B
The life forms of the parasite in the invertebrate host are different to the mammalian 
host. Figure 5 shows a 2-D representation of the parasitic life forms proboscis to the 
exterior the reduvid beetle. The beetle ingests the parasite as trypomastigote, which 
metamorphoses to the epimastigote to allow replication. It will then manipulate itself 
into the metacyclic trypomastigote form before excretion (defecation).
Figure 5 2-D diagrammatic representation of the reduvid beetle Colli 1993
, ^  MetacyclicTrypomastigote ^ Tiypomastigote
Epimastigote 
(inside beetle)
1.2.3 The Life forms of T, cruzi
The parasite has three life forms, amastigote, epimastigote and trypomastigote {Smyth 
1994). The higlily infectious trypomastigote form circulates in the bloodstream and 
invades cells to escape from the hosts’ immume system. In order to replicate, the 
parasite must manipulate itself into the amastigote form {Schenkman and Brines 
1994). It has to revert into the trypomastigote form to escape into the blood stream 
of the host to recirculate. Tins stage of the parasite life cycle has an important role in 
the enzyme activity: in the trypomastigote form, /raw.s-sialidase potential is greatest, 
^vhereas the amastigote life form shows no such enzymatic activity {Schenkman and 
Brines 1994). A digramatic representation of the three parasitic forms is illustrated in 
Figure 6.
Figure 6 The three life forms of T. cruzi : (a) amastigote (b) epimastigote
and (c) trypomastigote Smyth 1994
Nucleus
Kinetoplast
Trypomastigote
t :0 j
Amastigote Epimastigote 
1.2.4 T, cruzi life cycle
The complete life cycle of T. cruzi showing the manipulation of life forms within both 
the mammalian and insect vectors is shown below in Figure 7.
Figure 7 The life cycle of 71 cruzi (adapted from Smyth 1994)
MAN Disappearance
Organs ^
TRIATOMID BUG1
Epimastigote forms
Table 1 Definition of Figure 7
Man Insect
I. Bite A. Bite
2. Initial infection by faeces B. Infected blood taken up by bug
3. Amastigote forms multiply in heart or 
reticulo-endothelial
C. Multiplication in mid-gut spreading to hind- 
gut
4. Transformation of trypanosomes -  appear in 
peripheral blood
D. Transformation to metacyclic form in 
rectum
1.3 The Inflammation and Immune Responses
After the onset of the acute phase of Chagas’ disease, usually 30-90 days, there is a 
massive accelerated immune response by the human host. The mechanism for this 
activation is as yet unknown {Gazzinelli et al 1997). On the surface of both 
amastigote and tiypomastgote parasite form of the parasite aie abundant 
Glycophosphoinositol-linked (GPI) mucins (O-linked glycoproteins). Mucins are 
generally structurally important to endothelial cells for protection and lubrication. T. 
cruzi GPI mucins stimulate inflammatory macrophages to produce cytokines. It is 
believed that it is the GPI anchored structures, that stimulate this response {Gazzinelli 
et al 1997). Metacyclic trypomastigotes and epimastigote^  ^also have GPI mucins but
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these GPI anchors are not able stimulate a response. A possible explanation for this is 
that the amastigote and trypomastgote GPI anchors are structurally distinct, hence 
producing a different response {Gazzinelli et al 1997). Most patients produce a 
significant immune response (predominately IgG and IgM isotopes) to trypomastgote 
GPI mucins, most of the antibodies bled at this stage recognise Gala(l,3)Gal found in 
these mucins {Gazzinelli et al 1997).
1.3.2 Cell invasion
Sialic acid plays a major role in parasite cell invasion {Smyth 1994). The structure is 
shown below in Figure 8; sialic acid is transferred fi'om the host to the parasite, 
sialylating the trypomastgote. The deprotonated carboxylic acid of the sialic acid 
gives the parasite a net surface negative clwge assisting cell adhesion and hence cell 
invasion, Figure 9 {Schenkman and Vandekerckhove 1993).
Figure 8 Structure of sialic acid (NeuSAc)
HN
HO 
Me
Sialic acid (NeuSAc)
It is believed that trypomastigote ^ra«5'-sialidase removes sialic acid fi'om the cells of 
the host, transferring it onto itself, allowing the parasite to “stick” to the cell surface. 
The parasite is then engulfed into the cell by the process on endocytosis. These steps 
are illustrated below in Figure 9.
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Figure 9 The four steps of entry into mammalian cells by Trypomastigote 
Trypanosoma cruzi (adapted from Schenkman 1993)
* Sialic acid 
— ^ • rram-Sialidase
Sialic acid acceptor 
4 # # ^  Host cell "lectin"
)— Penetin, or other sialoadhesin
After invasion, the host produces an immune reaction, yielding a phagasome, which 
encapsulates the parasite {Schenkman and Frevert 1992). However, within a few 
minutes the parasite is free once more. It is beheved that /raw^-siahdase enables the 
parasite to escape more easily by disrupting the membrane of the phagosome 
{Schenkman and Vandekerckhove 1993). These conclusions were based on studies 
carried out on blood cells with a high sialic acid content.
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1.4 /rflWS-Sialidase reactions
/rara-sialidase has two activities: a hydrolase and a transferase activity {Scudder et al
1993). This enzyme is unique in that it preferentially catalyses the transfer reaction of 
sialic acid to mucin-like molecules forming an a2,3 bond with p-galactose acceptors 
on the surface of the parasite {Schenkman et al 1997). Although it is primarily a 
transferase, it does have some residual hydrolase activity. Figure 10. The transfer 
reaction is freely reversible.
Figure 10 Transfer of sialic acid by /ra/is-siaiidase
HO Parasite
OHOH /OH Transferase HO OHOHHO CO2CO2
ParasiteHost HO'AcHNHO'AcHN OHOH HOHO
Hydrolase
HOOH
OH
(Desialylated)
HO
OHHO-AcHN HO
1.4.2 Parasitic attachment of /‘rans-sialidase
rrara-Sialidase is attached to the surface of the trypomastigote via a GPI anchor. 
However it attachment to the epimastigote is trans-membrane. A diagrammatic 
representation of these points is shown in Figure 11. This diagram also shows the 
catalytic domain of rro/?5-sialidase.
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Figure 11 Schematic of tiypomastigote and epimastigote /mfis-sialidase
(adapted Schenkman and Nussenzweig 1992)
Papain Cleaveage
Membrane
Tiypomastigote
^ra«5-sialidase
Catalytic Domain
12 Amino Acid repeats 
GPI Anchor
Membrane
Epimastigote 
?ra«5“sialidase (Insect only)
After selected proteolysis using papain at the site indicated, a 70 kDa unit is left in 
which full enzymatic activity is retained. The 15 kDa cleaved fi*agment contains 12 
amino acid unit repeats located at the carboxyl terminal, which is attached to the 
parasite via a GPI anchor. This 15 kDa is not essential for enzymatic activity, stability 
or for correct folding of the protein dui'ing biosynthesis {Schenkman and Chaves
1994).
Significantly, other related sialidases and glycosidases catalyse both transfer 
and hydrolysis reactions but rates of the hydrolysis reactions are always much faster 
(typically greater than 100 times faster). The relationship between trans-siaMasQ and 
C. perfringens neuraminidase will be discussed further in Chapter 2.
1.4.3 ^raMf-Sialidase primaiy structure
The primary sequence of the T. cruzi sialidase has 1162 amino acids ai ranged into 
four domains {Takle and Cross 1993). It also contains three elements conserved in 
most sialidases. Figure 12 illustrates the percentage similarities of these and other 
related neuraminidases.
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Figure 12 Dendrogram of sialidase primary structures similarities based on 
identical amino acid residues (Biology of Sialic acids, Rosenberg).
Trypanosoma cruzi 
Trypanosoma rangeli 
Vibrio cholera 
Rattus rattus
Micromonospora viridifaciens - 
Actinomyces viscosus 
Clostridium septicum 
Clostridium perfringens ("large")- 
Clostridium perfringens ("small")- 
Clostridium sordellii 
Salmonella typhimurium
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1.4.4 Comparison of the mechanism of ^ra/fs-sialidase and with other 
neuraminidases
Sialidases are common place in many microbial pathogens, for example Salmonella 
typhimurium and Vibrio cholera amongst others. Sialidases have also been 
implicated in infections by Influenza A and B virus, and they have been therapeutic 
targets for many years. In Influenza A and B, the sialidase enzyme is responsible for 
the destruction of receptors, allowing the virus to spread and replicate {Bamford 
1995). It is this recognition of sialic acid by the Influenza receptor that has provided 
the biggest target for rational drug design {Bamford 1995). Most of the essential 
information on enzyme substrate recognition has been elucidated fi*om the x-ray 
crystal structure {Taylor et al 1995).
Sialidases have been isolated fi'om various mammalian tissues as well as 
bacteria and viruses {Taylor et al 1995). The divergence of location and structure of 
sialidases/neuraminidases creates a large super-family (approximately 40 members) of 
related enzymes {Taylor 1996). The relationship between some of these 
neuraminidases is illustrated below in Figure 13.
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An expansion of the legend of Figure 13 is shown below.
Hemaglutinin- 
Neuraminidase viruses 
(HN shown in Red)
Non-viral sialidase 
(shown in green)
Influenza 
neuraminidases 
(shown in blue)
Influenza 
neuraminidase 
(split into 9 NA sub- 
types, blue)
HEMA CDVO NANH CLOPE NRAM INBLN NRAM lALEN
HEMA PHODV NANH CLOPE2 NRAM INBVI NRAM lACHI
HEMA MEASA NANH CLOSO NRAM INBBE NRAM lAUSS
HEMA MEASE NANH SALTY NRAM INBMF NRAM lAPUE
HEMA MEASH 8511 TRYCR NRAM INBOR NRAM lAWIL
HEMA MEASY TCTS SA85 NRAM INBSI NRAM lAPAR
HEMA MEASI TCTS 121 NRAM INBHK NRAM lAHAI
HEMA RINDK TCTS 154 NRAM INBUS NRAM lAHTE
HEMA RINDR TCTS 193 NRAM INBMD NRAM lAHKI
HEMA RINDL TCTS Y NRAM INBLE NRAM lAHNO
HEMA PI3H4 TCNA TRYCR NRAM lAKIE NRAM lAHMI
HEMA PI3HA TRANG NRAM lAHSO
HEMA PI3HU TRANG2 NRAM lAHAL
HEMA PI3HV TRANG4 NRAM lAHGD
HEMA_PI3HW (Human and mouse 
MHC/lysosomal)
NRAM JAM AE
HEMA PI3HT G9 NRAM lAGFN
HEMA PI3HX NANH MOUSE NRAM IADM2
HEMA PI3B LEECH NRAM lATKL
HEMA SENDS NANH CLOTE NRAM lADBU
HEMA SENDJ NANH CLOPE3 NRAM IADH2
HEMA SENDZ NANH CLOSE NRAM lADCH
HEMA SENDF NANH STREP NRAM IADU3
HEMA_SENDH (Mammalian
cytosolic)
NRAM JAHJI
HEMA PIIHW NANH CHO NRAM lAQIT
HEMA NDVC NANH RAT NRAM IASH2
HEMA NDVJ (Bacterial) NRAM JACKQ
HEMA NOVI NANH ACTVI NRAM lACKR
HEMA NDVD NANH ACTVI2 NRAM IAH04
HEMA NDVU NANH MICVI NRAM IAVI7
HEMA NDVQ NANH VIBCH NRAM lAUDO
HEMA NDVA (Bacteriophage) NRAM lABAN
HEMA NDVM ENAN BPKIE NRAM lASWK
HEMA MUMPM ENAN BPKIF NRAM IANT6
HEMA MUMPR NRAM lATOK
HEMA MUMPl NRAM IARI5
HEMA SV5CM NRAM 1AH03
HEMA SV5CP NRAM lARUE
HEMA SV5 NRAM lAWHM
HEMA SV5LN NRAM lATRA
HEMA PI2H NRAM lAFPW
HEMA PI2HT NRAM lAHCO
HEMA SV41 -
HEMA PI4HA
Figure 13 Dendrogram comparing all known neuraminidases (This diagram 
is the property of Prof. G. L. Taylor, University of Bath, UK and is reproduced with his permission).
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It is suggested that bacterial sialidases are a causative agent of microbial infections in 
animals, whereas mammalian neuraminidases largely catabolise sialoglycoconjugates 
{Taylor 1996). Sialidases can be important in the regulation of cell surface sialic 
acids, for example in the immune system, where the life time of certain ciiculating 
cells has to be regulated {Taylor 1996). It is the fine adjustment of sialidase versus 
sialic acid, wliich is paramount to maintaining this balance in biological systems. It is 
the exploitation of these terminal sialic acids by pathogens which causes disease.
There seems to be significant variation, however, in the mechanism of action 
of various neuraminidases. Two distinct families of sialidases are apparent: one has 
greater eirzymatic activity when a divalent metal is bound in the co-ordination site; the 
other family show no significant increase in activity in the presence of metal ions 
{Taylor et al 1993). In some cases, electrostatic interactions between enzyme and 
sugar are important and in other cases hydrogen bonding at the anomeric centre is 
significant, since these charge interactions can assist with the stabilisation of the 
transition state and can control the overall stereochemistry of the reaction. Generally, 
one or more carboxylic acids in the binding site catalyse or stabilise the reaction.
1.4.5 Viral Neuraminidases
Viral neuraminidases are responsible for the promotion of infection in mammalian 
cells {Von Itstein et al 1993) . Since self-agglutination of new viial particles may stop 
replication of the disease, viral neuraminidases remove the key sugar involved, namely 
sialic acid.
1.4.5.2 Influenza A virus neuraminidase
Influenza vii'us neuraminidase is tetrameric, 240 kDa in size, consisting of four 
identical monomer units, joined by eight disulpMde bridges. Each monomer 
incorporates a protein fold known as a super-barrel or p-propeller {Taylor et al
1995). The pseudo-symmetrical arrangement of this structuie comprises of four p- 
sheets antiparallel to each other, repeated six times (i.e. six propeller blades). This 
gives rise to a six fold rotation axis about its centre. All sub-types of Influenza A and 
B virus duplicate this motif, although the amino acid sequence (conservation identity 
of < 40 %) would not suggest this {Taylor et al 1995). Influenza A is classed as an
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RNA virus, having an RNA genome in a membrane envelope. The membrane itself 
(1000 A in diameter) envelopes three proteins. The two most important proteins in 
the membrane are hemaglutinin (HA) and neuraminidase, both trans-membrane 
glycoproteins (Portner et al 1995). HA is responsible for cell invasion via receptor- 
mediated endocytosis, using sialic acid fi'om the surface of vulnerable cells in the 
respiratory tract {Partner et al 1995). Before HA releases the viral RNA into the 
cytosol, neuraminidase must cleave the terminal sialic acid to prevent the virus being 
removed and destroyed by the host. The enzymatic activity of the virus improves 
significantly with the binding of Ca^ ,^ hydi'olysis appealing to proceed with retention 
of configuration {Von Itstein 1995).
1.4.6 Bacterial neuraminidases
Bacterial sialidases have limited sequence homology, approximately 30 % to each 
other, although all contain conserved motifs: RIP/RLP (Arg-Ile/Leu-Pro) followed by 
an Asp box (Ser/Thr-X-Asp- [X] -Gly-X-Thr-Trp/Phe) where X represents any amino 
acid {Taylor et al 1993). The conservation between bacterial and viial sialidases is 
lower still at approximately 15 %. Many bacteria produce sialidases to remove sialic 
acid as an energy and carbon soiuce. The bacterial cell is equipped with the 
necessary cell organelles to deliver and catabolise sialic acid {Taylor et al 1996). 
Bacterial sialidases vary in size between 40-120 kDa and are mostly monomeric units, 
either anchored to the cell surface, or aie soluble when secreted {Taylor et al 1996).
1.4.6.2 Salmonella typhimurium LT2 - neuraminidase
Salmonella typhimurium neui aminidase is 42 kDa and has one of the simplest protein 
architectures, consisting of only one propeller fold characteristic of the 
neuraminidase super-family. The primary protein arrangement is four p-sheets 
organised antiparallel relative to each other, repeated six times, to form the propeller 
type arrangement {Taylor et al 1995). Between the p-sheets He large regions of 
hydrophobic residues, aiding the stabilisation of this secondary element. This enzyme 
is a monomer of approximately 391 residues and it is believed that proton donation is 
requiied for leaving group depaiTure {Sinnott and Laver 1994). It does not bind Ca^  ^
to enhance enzymatic activity and contains only one disulphide bridge {Sinnott and
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Laver 1994),
1.4.6.3 Vibrio cholera neuraminidase
Vibrio cholera neui'amiiiidase is a larger bacterial enzyme, 82 kDa, and has tliree 
protein regions: the typical nemaniinidase fold, a p-propeller consisting of 54 p-sheets 
with five segments containing a-helices and two lectin-containing domains at either 
side flanking this fold {Taylor et al 1994). This lectin domain contains 200 residues, 
making up seven p-sheets and six antiparallel p-strands {Taylor et al 1994). The 
neuraminidase is pait of pathogenic mucinase multi-enzyme complex. This complex 
includes a proteinase and an endo-p-N-acetylhexosaminidase. Its role is to cleave 
terminal sialic acid from glycoconjugates to create GMi (the cholera toxin receptor) 
on the lining of the gastrointestinal tract {Taylor et al 1994). Cholera toxin can then 
attach itself to this binding site and invade cells. The lipid fluidity created by the 
neuraniinidase assists this process. In this enzyme, the sugar adopts a chair 
conformation and the hydrolysis proceeds with retention of configuration {Von Itstein 
et al 1995), probably via a double-displacement mechanism {Sinnott and Guo 1993). 
Vibrio cholera neuraminidase requkes Ca^  ^at the catalytic site to allow it to fijnction 
correctly {Sinnott and Guo 1993).
14.6.4 Micromonospora viridifaciens neuraminidase
A non-pathogenic Actinomycete soil bacteria contains a neuraminidase, 
Micromonospora viridifaciens. M. viridifaciens neuraminidase contains the typical 
super-barrel fold (41 kDa) found in the neuraminidase super-family. However, tliis 
enzyme has an additional lectin motif made up of antiparallel p-strands, forming an 
“arm” arrangement (~ 30 kDa). The 3-D crystal structure of Micromonospora 
viridifaciens neurarninidase is shown below in Figure 14 {Taylor et al 1995, 1996).
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Figure 14 3-D ribbon drawing of the crystal structure of Micromonospora
viridifaciens neuraminidase {Taylor et al 1995)
The catalytic domain of T cruzi /raw '^-sialidase has a molecular weight of 70 kDa 
encompassing a 40 kDa p-propeller fold and two lectin domains, comparable with 
Micromonospora viridifaciens neuraminidase. It is therefore acceptable to predict 
that the structure of Micromonospora viridifaciens neuraminidase, which has more 
than one binding site for galactose would be a feasible model for T. cruzi trans- 
sialidase. Hence it is reasonable to assume that there is more than one galactose 
binding site in T. cruzi /ro«5-sialidase, possibly having a similar role to the Influenza 
virus trans-membrane glycoprotein, HA. Micromonospora viridifaciens 
neuraminidase has a similar sequence homology and activity to Clostridium 
perfringens neuraminidase {Schauer et al 1992). The TV-terminal sequencing of C. 
perfringens neuraminidase is similar to that of T. cruzi /raw^-sialidase, as well as that 
of Micromonospora viridifaciens {Pereira 1995).
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1.4.6.5 Macrobdella decora sialidase
Macrobdella decora sialidase has a multi domain structure, with a similar topology to 
that Vibrio cholera neuraminidase, with a mass of ~ 80 kDa. Two lectin domains 
flank the catalytic domain of this sialidase (Two 1998). The catalytic domain is
organised as p-propeller fold creating pseudo six-fold symmetiy. Isolated North 
American {Macrobdella decora) leeches have produced some unusual enzymes. As 
well as possessing a typical sialidase, they also have an unusual sialidase, sialidase L, a 
2,3-specific hydrolase that yields the (transient) 2,7-anhydro equivalent of the 
commonly produced sialic acid, shown in Figure 15, {Sinnott et al 1993, Li et al
1996). It appears to have a similar active site to Influenza virus and Micromonospora 
viridifaciens (Xwol998). The release of 2,7 anhydro-sialic acid, indicated that 
Macrobdella decora sialidase transfers sialic acid glycoconjugates instead of 
hydrolysing them, and requires the glyceryl side chair in an axial position during the 
transition state (Iwol998).
Figure 15 Structure of 2,7-anhydrosialic acid
AcHN
HO
OH
HO
O
1.4.7 Sequence alignments of Trypanosoma cruzi ^raws-sialidase with related 
sialidases/neuraminidases
The amino acid sequences of a variety of neuraminidases were analysed and then 
compared to the amino acid sequence of Trypanosoma cruzi /rarw-sialidase. The 
results are shown below in Table 2.
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Table 2 Amino acid sequence alignment of Trypanosoma cruzi trans- 
sialidase with related sialidases/neuraminidases
Salmonella tvDhimurium 
Neuraminidase 61 120 15
R:^92^
50
r 2 4 6 _ ^
46
y 3 4 2 ^
19 294
^ 6 3 5
Influenza A Virus 
neuraminidase
D 1 5 1 ^
27 99 32 62 35 19
E 4 2 5 _ ^
287
r 712
TrvDanosoma cruzi 
trans-siaiidase
D 19 /2 7 /2 8 _ ^
56/48/47 110 15
R 2 0 0 _ ^
53 44
y 2 9 7 ^
20 ?
Vibrio Cholera 
neuraminidase 81
r 118_^
107 26 61 307 121
y 7 4 0 ^
16
E756
Micromonospora
Viridifaciens
neuraminidase
97
r 2 4 8 ^
100
r 3 4 8 ^
30 60 ?
We can see that Trypanosoma cruzi /ra«5'-sialidase has amino acid residues which aie 
conserved in the catalytic area of Salmonella typhimurium and Influenza A virus 
neuraminidase. It is also possible to align the amino acid sequence of 
Micromonospora viridifaciens neuraminidase with Vibrio cholera neuraminidase. 
However there does not appear to be any conservation with Trypanosoma cruzi 
^raws'-sialidase (or Salmonella typhimurium and Influenza A virus neuraminidase). 
Any of the amino acids mentioned above may be important in the neuraminidase 
mechanism of action or provide the necessary residues for hydrogen bonding at the 
active site of the enzyme.
1.5 Cloning and expression of frawx-sialidase
The genetic structure of T. cruzi /raw^-sialidase contains many features common to 
neuraminidases. Notably, it contains information about the make up of the enzymatic 
domain on the A-terminus and also the antigenic domain, the shed acute phase antigen
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(SAPA) at the C-terminus (12 amino acid repeats in tandem) (Frasch et al 1995, 
Schenkman and Vandekerckhove 1993, Schenkman and Eichinger 1993). By a 
combination of site directed mutagenisis followed by enzyme activity studies, it was 
noted that only 2 of the 624 amino acids of the sequence are actually essential for full 
transferase activity {Frasch et al 1995). Mutation of Tyr (in any way) caused the 
enzyme to lose all activity and Pro mutation resulted in partial activity only. It is 
suspected that these residues are in the active site {Frasch et al 1995). When these 
residues and the sunounding ai*ea are compared to the active site of Salmonella 
typhimurium neuraminidase, fourteen of the twenty residues of the Salmonella 
typhimurium enzyme are either conserved, or in a comparable positions (including 
Tyr ^^ )^ to /^ raw.y-sialidase.
1.5.2 Kinetic profile of /m/f^-sialidase
Studies carried out on recombinant /rawi'-sialidase concur with those completed using 
wild-type protein, the temperature being critical to the behaviour of the enzyme. The 
hydrolysis rate of sialyl lactose by ^ra«5-sialidase steadily increases up to 35 °C 
{Schenkman et al 1997). However, the transferase reaction rate is maximum at a 
temperature of 13 °C (approximately). Also, most neuraminidases function best in an 
acidic medium (around pH5), hence the pH 8 optimum for ^ram’-sialidase is unusual. 
The pH and temperature dependence of T. cruzi ^n^a^-sialidase is illustrated below in 
Figure 16.
Figure 16 Diagram of pH and temperature dependence of the transferase 
activity of ^ ra/fs-sialidase Scudder et al 1993
g  100IIII
6 0 -
Temperature °C.SI 2 4 6 8 10 12 10 20 30
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1.5.3 Prospective mechanism for trans-sialidase
It is possible that ^rara-sialidase catalysed hydrolysis may proceed with retention of 
configuration, since all other neuraminidases investigated proceed with retention 
{Taylor et al 1993, 1994, 1995, Von Itzstein and Pegg 1992 and Von Itzstein and 
Wilson 1995).
There are two main postulates:
1. The enzyme has two binding sites one for the sialic acid (donating substrate) 
and one for the accepting substrate, allowing simultaneous binding. However, this is 
unlikely as there is little precedent for two binding sites in neuraminidases. However 
studies carried out to compare the hydrolysis and transfer reactions using 4-methyl- 
irmbelliferyl-iV-acetyl-neuraminic acid {Schenkman et al 1997), indicate that the 
transfer reaction does not increase (at any temperature) with an increase m lactose, 
indicatmg that the rate limiting step is the release of the aglycon {Schenkman et al
1997). There may also be two binding sites for ^raw '^-siahdase, i.e. a donor and an 
acceptor binding site.
2. The enzyme may have only one binding site, the donor and acceptor having to 
enter and leave from the same site to maintain the retention of configuration. This 
would require a relatively long-lived reaction intermediate i.e. a glycosyl 
oxocarbonium ion, a sialyl-enzyme (covalent) complex or an a-lactone mteimediate. 
Figures 17A and B {Von Itzstein et al 1995, Sinnott et al 1992, Sinnott and Guo 
1993).
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Figure 17A An electrostatic or covalent interaction followed by hydrolysis of 
sugar-enzyme complex via H2O
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interconvesion and 
subsequential loss of 
axial ROH
OR
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Charge stabilised 
oxocarbonium ion 
intermediate assisting 
the attach of H2O 
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Figure 17B A short-lived a-lactone intermediate
Carboxyl group particiation 
in the formation of an 
O a-lactone and the loss of ROH
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a-lactone intermediate
H2O catalysed ring opening 
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Aims and objectives
To isolate T. cruzi fra«5-sialidase and puiify recombinant using standard protein 
purification techniques to the level of a single band on SDS-PAGE (silver stained).
To develop a sensitive, rapid spectrophotometric assay for /ram-siahdase
To assess the acceptor specificity of T. cruzi trans-siaMasQ using:
- Systematically modified acceptors (synthetic compound libraries)
- Fragments of the naturally occurring mucin glycans
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Chapter 2
Assay development
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2.1 Assay development
Purification of an enzyme from a crude E. coli extract requires a method (i.e. an 
assay) of establishing whether or not the enzyme is present and the quantity of 
activity. The assay should be relatively simple, preferably giving an instantaneous 
read-out to identify active fractions at a glance. It was necessary to develop such a 
method to assist the elucidation of an enzyme profile for /raw5'-sialidase.
2.1.2 Neuraminidase assays - Spectrophotometric
Neuraminidase (hydrolase) assays are well documented in the literature (Sinnott and 
Guo 1993 and Sinnott et al 1993). These assays monitor the hydrolysis rates of 
neuraminidases, generally using Neu5 Ac-O-PNP as a substrate, the enzyme cleaving 
the bond between the sugar and j^-nitrophenol. The ^-nitrophenol liberated is 
monitored at 400 nm. This process can be adapted to use methyl umbelliferyl 
glycosides as alternative substrates, the fluorescence of the product being monitored 
at 365 nm {Schauer et al 1997), Figure 18.
Figure 18 
(4-MU)
Structure of pam-nitrophenol (PNP) and 4-methylumbeIliferone
j!7flrra-Nitrophenol (PNP) 4-Methylumbelliferone (4-MU)
A study was carried out on /row^'-sialidase and C. perfringens neuraminidase (loosely 
based on the spectrophotometric assay designed by Scudder et al 1993). trans- 
Sialidase and Clostridium perfringens neuraminidase were both assayed with the 
substrate Neu5Ac-O-PNP. The use of C. perfringens neuraminidase in an assay has 
been outlined by Quash et al 1992 and Schauer et al 1991. Shown below in Figure 
19 is a plot of the ^ra«j-sialidase assay (Neu5 Ac-O-PNP donor substrate) in the 
presence and absence of a potential acceptor substrate, lactose.
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Figure 19 /ra/fs-Sialidase in the presence and absence of a potential acceptor
substrate, lactose (30 min incubation)
0.14
0.12
B 0.1a 0.08
0.06
< 0.04
0.02
0
A B
/ra/i5-Sialidase
neuraminidase
Legend Incubations
A /ra«5-sialidase without lactose (Neu5Ac-0-PNP donor)
B tra«5-sialidase with lactose (Neu5Ac-0-PNP donor)
This graph indicates that the transferase rate of /ra«5-sialidase is significantly greater 
than that of the hydrolase. A similar experiment was carried out using C. 
perfringens neuraminidase in the presence and absence of lactose. The result is 
shown in Figure 20.
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Figure 20 C. perfringens neuraminidase in the presence and absence of a
potential acceptor substrate, lactose (30 min incubation)
SaI<
C. perfringens 
neuraminidase 
incubations
Legend Incubations
A C. perfringens neuraminidase without lactose (Neu5Ac-O-PNP donor)
B C. perfringens neuraminidase with lactose (Neu5Ac-O-PNP donor)
Figure 20 indicates that C. perfringens neuraminidase is a good hydrolase of 
Neu5 Ac-O-PNP, the presence of lactose having an insignificant effect on the release 
of PNP. By comparison, /ra«5-sialidase is a poor hydrolase of Neu5 Ac-O-PNP, 
although still having significant hydrolase activity. This study suggests that 
Neu5Ac-0-PNP is a reliable substrate to measure hydrolase activity of C. 
perfringens neuraminidase, but is an unsuitable substrate to measure trans-sialidase 
transferase and hydrolase reactions.
2.2 Transferase assays -  Radiochemical
Radiochemical assays for /ra/?.s-sialidase monitor the incorporation of a 
radiochemical precursor, in this example ['"^ C] lactose {Pereira et al 1995, Vetere et 
al 1996). This incorporation process, shown below in Figure 21, results in the 
formation of anionic radio labelled Neu5Ac*GalGlc which can be separated from 
uncharged material by anion exchange chromatography.
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Figure 21 Incorporation of [^ '*C] lactose
NâsAcGalGlc + *GalGlc
©Neu5Ac*GalGlc + GalGlc 
^Radiochemical isotope incorporation
rrüfM -^Sialidase reversibly transfers sialic acid from sialyl lactose on to lactose. 
Sialy 1-transferase activity can be monitored by this assay but it is not a convenient 
assay to rapidly screen column fractions. It is also undesirable since the assay uses 
radiochemicals making it a potential biological hazard, and involves a 
chromatographic procedure for separation on QAE-Sephadex media. This process 
can be arduous due to the nature of the media and separation under gravity.
2.3 Comparison of ^ r«M;y-sialidasc transferase and hydrolase activities
Since ^ra«5-sialidase is both a hydrolase and a transferase, an assay to measure both 
of these rates of reaction would best serve the rapid screening of protein purification 
column fractions. Hence a spectrophotometric coupled assay (mark I) was designed 
for ^raws-sialidase. This assay was designed to work as follows: Neu5Aca(2,3)Galp- 
0-PNP acts as a donor substrate for /r«w.s-sialidase and lactose as an acceptor. (From 
previous expeiiments it has been established that Neu5Ac-Gal-PNP is a better 
substrate for rra/75-sialidase than Neu5Ac-O-PNP). (5-Glucosidase (crude, almonds) 
containing some p-galactosidase activity was used to hydrolyse the resulting Galp-O- 
PNP bond and release PNP which was monitored at 400 nm. The coupled assay 
(mark I) is shown below in Figure 22.
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Figure 22 Coupled assay for ^riiws-sialidase (mark I)
HO OH ©ÇO2  OH OH 
Neu5Aca(2,3)Galj3-0-PNP
rraw-sialidase ho HO2 p-glucosidase 
(p-galactosidase)
^  Galactose
OH \L_J 
Galp-O-PNP
pH 6.5
HO
Hydrolase
Transferase Lactose
OHHO
OHHO OH
OH HOOH
OHHO OH
Neu5 Aca(2,3)Galp( 1,4)Glc
* Intermediate, not proven
This assay proved successful initially as it was a quick and sensitive technique for 
detecting the presence of /r««5'-sialidase. Shown below in Figure 23 is a plot 
comparing the coupled assay (measuring both hydrolase and transferase activities) as 
well as data from the previous spectrophotometric assay (using Neu5Ac-PNP as a 
substrate). This representation clearly indicates the preference of a disaccharide 
substrate over a monosaccharide donor for ^mm-sialidase.
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Figure 23 Comparison of /ra/ts-sialidase transferase and hydrolase activities
with Neu5Ac-0-PNP and Neu5Aca(2,3)-Gal-p-0-PNP substrates
< 0.2
trans -sialidase 
incubations
Legend Incubations
A Neu5Ac-0-PNP, /ra«5-sialidase without lactose
B Neu5Ac-O-PNP, /m/ts-sialidase with lactose
C Neu5Aca(2,3)-Gaip-0-PNP, tram-sialidase without lactose
D Neu5Aca(2,3)-Gaip-0-PNP, tra/75-sialidase with lactose
2.5 Comparison of C  perfringens neuraminidase activity with and without 
an acceptor
The coupled assay (mark I) (using the disaccharide donor substrate, Neu5Aca(2,3)- 
Gaip-O-PNP was set up replacing r^aws’-sialidase with C. perfringens neuraminidase. 
It has already been established for trans-sialidasQ that Neu5Aca(2,3)-Galp-0-PNP is 
a more reliable substrate. It was expected that the presence of lactose would be 
insignificant to C. perfringens neuraminidase. Figure 24 shows the results of this 
study (combined with previous findings using Neu5 Ac-O-PNP as a donor).
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Figure 24 
acceptor
Comparison of C. perfringens neuraminidase with and without
0.71
0.6
B 0.5a 0.4
< 0.3< 0.2 i
0.1^
0
B D
C. perfringens 
neuraminidase 
incubations
Legend Incubations
A Neu5Aca(2,3)-Galp-0-PNP, C. perfringens without lactose
B Neu5Aca(2,3)-Galp-0-PNP, C. perfringens with lactose
C Neu5Ac-0-PNP, C. perfringens without lactose
D Neu5Ac-O-PNP, C. perfringens with lactose
As suspected the presence of lactose had no significant effect. The absorption 
change using the Neu5Aca(2,3)-Galp-0-PNP donor is slightly lower than using 
Neu5 Ac-O-PNP. This is probably as a result of a lower free PNP background and is 
insignificant.
2.6 Coupled assay for tra/is-sialidase using Galp(l,3)GlcNAcp-0-0ctyl as an 
acceptor (mark II)
The first coupled assay for ^ra«5-sialidase was successful in the initial stages, 
however latterly it became problematic since lactose was being degraded by the p- 
galactosidase activity which was present in this “one-pot” assay. Also the acidic pH 
resulted in the donor sugar being subject to spontaneous hydrolysis and hence 
releasing PNP. In order to combat this problem the pH was increased. As a result of 
the rise in pH, another p-galactosidase had to be selected, since the pH for maximum 
enzymatic activity is 6.0 for the p-glucosidase (crude, almonds). p-Galactosidase 
from E. coli with a maximum activity at pH 7.3 was selected. Since this pH is just 
above neutral it helps to prevent spontaneous hydrolysis of the donor substrate.
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However, this brought a further complication in that lactose, the acceptor sugar, was 
now subject to hydrolysis by the p-galactosidase, since lactose is the natural substrate 
for the E. coli enzyme. Glucose release, cleaved by p-galactosidase from a variety of 
potential substrates based on the general structure Galp(l,X)GlcNAc was assessed 
with a commercially available {Sigma Chemicals Ltd) glucose testing kit and by 
T.L.C. It was found that lactose would prove unsuccessful as an acceptor and hence 
another Gal-X had to be selected which would not be subject to the same level of 
hydrolysis. Galpl(l,3)GlcNAcp-0-0ctyl was selected as an alternative and tested 
with p-galactosidase and the glucose testing kit. It was found to be stable to 
hydrolysis by the p-galactosidase and hence it was decided to proceed with this sugar 
as the new acceptor substrate. The results of the coupled assay (mark II) are shown 
below in Figure 25. The assay was carried out for 30 minutes.
Figure 25 Results of the coupled assay for fra/is-sialidase (mark II) (30 Min
incubations)
<<  02
A B C  
thvff-Sidkiase inatetions
Legend Incubations
A Water (10^1)
B Lactose (5 mM, 10|il)
C Galp(l,3)GlcNAcp-0-0ctyl (5 mM, 10 1^)
This graph clearly indicates that trans-sialidasQ reactions are significantly better with 
the substrate Galp(l,3)GlcNAcp-0-0ctyl. The coupled assay (mark II) is outlined 
below in Figure 26.
Figure 26 Coupled assay using Galp(l,3)GlcNAcp-0-0ctyl as an acceptor
(mark II)
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* Intermediate, not proven
The second assay using Galp(l,3)GlcNAcp-0-0ctyl as a substrate has proved much 
more successftil with the self-cleavage of the donor now negligible. Studies with 
this assay show that there is a reliable measurable hydrolase activity for trans- 
sialidase with a disaccharide donor substrate.
37
2.7 Spectrophotometric coupled assay (mark II) using variable 
concentrations of donor substrate
The transfer rate of /r««^-sialidase is five times faster than that of the hydrolysis rate, 
and the non-enzymatic rate is only one twelfth as fast as the transfer, this is shown 
below in Figure 27.
Figure 27 tmwv-sialidase: variable concentrations of Neu5Aca(2,3)-Galp-0-
PNF donor substrate with and without acceptor (mark II assay)
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No acceptor (Red square) (-) Galp(l,3)GlcNAcP-0-0ctyl
Acceptor (Blue diamond) (+) Galp(l,3)GlcNAc(3-0-Octyl (ImM)
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Using the above data, we can construct double reciprocal plots according to 
Michaelis-Menten kinetic parameters. These are shown below in Figure 28A and B.
Figure 28A Plot of 1/S vs 1/v for /ra/i5-sialidase, the transferase
0.60.2 0 .4 0.80.2
1/[S] mM
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Figure 28B Plot of 1/S vs 1/v for /raTis'-sialidase, the hydrolase
0.2 0 .4 0.6
0 .4 0.2
1/[S] mM
The error on these graphs (Figures 28A and B) is of the magnitude of +/- 20 %. 
This data is therefore does not allow us to obtain accurate Æm or Fmax values for 
/ra«5 -sialidase activities. The large error is due to the relative instability of the 
donor substrate. However the data acquired does allow us to make an estimation of 
Km and Fmax for /raw^-sialidase. The lines drawn in above are estimated by eye 
(and are not as a result of linear regression). The results were estimated as follows: 
trans-sm\ïéd.sQ, the transferase has a = 7 mM and a Fmax = 2 nM min'^ whereas 
/Tûrw '^-sialidase the hydrolase has a = 4 mM and a F,nax = 0.5 nM min'\ The data 
is sufficient for the general comment that the Am value for /raw^-sialidase (hydrolase 
and transferase) is in the low mM range. This is a reasonable result and comparable 
with the hydrolysis ofp-nitrophenol glycosides by other neuraminidases.
The Am value for the hydrolysis of NeuS Ac-O-PNP for some of these enzymes is as 
follows. Vibrio cholera neuraminidase (pH 5.0, 37®C) Am =1.63 mM {Sinnott and 
Guo 1993), Influenza virus neuiaminidase (pH 6.0, 37°C) Am =1.17 mM {Sinnott
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and Guo 1993), Salmonella Typhimurium neuraminidase (pH 5.5, 37°C) Km = 0.87 
mM {Sinnott et al 1994) and Macrobdella decora neuraminidase (pH 5.5, 37“C) Km 
- 5 .1  mM {Sinnott et al 1993).
2.8 Inhibitor study carried out with /mifs-sialidase and C  perfringens 
neuraminidase
An inhibitor study was carried out on ^rawi'-sialidase and C. perfringens 
neuraminidase using the established neuraminidase inhibitor 2 ,3 -dehydro-2 -deoxy- 
Neu5Ac, shown below in Figure 29A {Von Itzstein and Pegg 1993, Von Itzstein et al
1993).
Figure 29A 2,3-dehydro-2-deoxy-Neu5Ac
HO OH
O©
AcHN
HO
HO
^ra«5-Sialidase and C. perfringens neuraminidase were incubated with 2,3- 
dehydro-2-deoxy-Neu5Ac, which acts as an inhibitor of C. perfringens 
neuraminidase, but not /ra«.y-sialidase. A comparison of relative hydrolase activity 
of C. perfringens neuraminidase and transferase activity of trans-sialidasQ with and 
without 2,3-dehydro-2-deoxy-Neu5Ac (inhibitor) present was calculated. The 
relative turnover rate calculated and the results are illustrated below in Figure 29B.
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Figure 29B Inhibitor study carried out with C perfringens neuraminidase
and /ra/ts-sialidase
8o
J<I
A B C D 
Enzyme inhibition study
Legend Incubations
A /ra«5-sialidase (-) Inhibitor (1 mm)
B /rans-sialidase (+) Inhibitor (1 mM)
C C. perfringens (-) Inhibitor (1 mM)
D C perfringens (+) Inhibitor (1 mM)
trans-SialidasQ activity with inhibitor present is > 90 %, whereas C. perfringens 
neuraminidase activity is < 5 % when there is inhibitor present. This result confirms 
that 2,3-dehydro-2-deoxy-Neu5Ac is an inhibitor of C. perfringens neuraminidase 
but not sialidase.
2.9 Summary
It has been well documented that /ra«.y-sialidase is preferentially a sialyl-transferase, 
although it does possess some hydrolase activity {Scudder et al 1993). By assaying 
trans-sialidase with both Neu5Aca(2,3)-Gal(3-0-PNP as well as the commonly used 
Neu5Ac-O-PNP {Sinnott and Guo 1993 and Sinnott et al 1993), it was established 
that rra/î^-sialidase favours a Neu5Aca(2,3)-Galp-0-PNP as a donor sugar. Hence a 
spectrophotometric coupled assay (mark I) using Neu5Aca(2,3)-Galp-0-PNP as a 
donor substrate was developed for /ram-sialidase. This also incorporated an 
acceptor substrate, lactose and p-glucosidase (with p-galactosidase activity). This
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assay was a little unreliable due to the acid instability of the Neua(2,3)Galp-0-PNP. 
This assay was modified slightly to give fra«.y-sialidase spectrophotometric assay 
(mark 11). In the r^fl«5 -sialidase assay (mark 11), lactose is replaced with 
Galp(l,3)GlcNAcp-0-0ctyl and the pH was increased from 6.5 to 7.3. This is now a 
reliable assay for the rapid assessment of fraw^-sialidase activity (Le. in protein 
purification column fractions).
Using the coupled assay (mark 11) i&n and Fmax for trans-smlidasQ were measured 
with increasing concentrations of Neu5Aca(2,3)-Galp-0-PNP substrate and a fixed 
amount of Galp(l ,3)GlcNAcp-0-0ctyl or H2O. The results were estimated at: 
/ra«5 -sialidase (transferase) Am = 7 mM and Fmax = 2 nM min ' 
trcms-smlidasQ (hydrolase) are Am = 4 mM and Fmax = 0.5 nM min'
Using the coupled assay (mark II) it has also been shown that C. perfringens 
neuraminidase is inhibited at ImM, by a known neuraminidase inhibitor 2,3- 
dehydro-2-deoxy-Neu5Ac {Von Itzstein and Pegg 1993, Von Itzstein et al 1993). 
/raw.s-sialidase, however is not inhibited at ImM.
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Chapter 3
tmw-Sialidase synthetic 
substrate recognition
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3.1.1 Development of glycosyl transferase inhibitors
Carbohydrates have a role to play in many biological functions on the surface of 
cells, as well as being required for energy consumption and structural properties. 
Modern techniques have greatly assisted the location of carbohydrates within 
biological systems. Almost all surface proteins are glycoproteins {Tolvanen et al 
1996) and the nine commonly used monosaccharides in their pyranose forms found 
in biological systems are (D-Glc, D-Gal, D-Man, D-Fuc, D-Xyl, D-GlcNAc, D- 
GaDSfAc, NeuSAc) {Hindsgaul et al 1997).
The biosynthesis of cell surface oligosaccharides is performed by glycosyl 
transferases. Hence glycosyl transferases are a potential target for therapeutics, since 
in theory they have the ability to cause structural modifications to cell-surface 
glycoconjugates. In order to do this successfully, it is necessary for the enzyme- 
substrate binding model to be established and a minimum requirement for acceptor 
substrate specificity to be identified. This should help to prevent affecting any other 
glycosylation processes. The mapping of the key interactions of an enzyme binding 
site is usually carried out by assaying the enzyme with a systematically modified 
series of substrate analogues to indicate the functional groups which are paramount 
in the glycosyl transferase substrate-interaction. There is an important interaction 
between the hydroxyl at the glycosylation position on the acceptor sugar (i.e. C3 on 
galactose in /rûf«.s-sialidase binding site) and the binding site in some glycosyl 
transferases (Hindsgaul et al 1997).
3.1.2 Systematically modified Galp-O-Octyl library
It has been well documented that Trypanosoma cruzi trans-sialidasQ will only 
transfer sialic acid onto the three position of a terminal galactose moiety when an 
acceptor sugar is available. In an attempt to firlly characterise the enzyme and its 
recognition of galactose, an investigation was carried out using synthetically 
modified galactose. Galactosep-O-Octyl was modified at the three, four and six 
hydroxyl positions by replacing the OH with either H, F, OMe or NH2 to create a 
library of modified octyl-galactosides. The synthesis of these compounds was carried 
out by Todd Lowary, Alberta, Canada. These galp-O-Octyl analogues had been 
synthesised for a study investigating the active site of glycosyl transferases
45
responsible for A and B blood group biosynthesis {Hindsgaul et al 1993). The 
modifications to Galp-O-Octyl are illustrated below in Figure 30.
Figure 30 Synthetically substituted Galp-O-Octyl library {Lowary et al 1993)
OH OH 
OH
Octyl
OHOH
HOHO Octyl Octyl
OH 
2 (1,11,lit,iv)
X(i) = H X(ii) =OMe
X (iii) = F X (iv) = NHz
OH 
3 (l,ii,ni,iv)
The compounds listed above were one of the components which were coupled (to 
fucose) to give a library of potential inhibitors, based on the general structure 
Fuca(l,2)Galp-0-0ctyl, a known acceptor of glycosyl transferases {Lowary et al
1994). The glycosylation of this structure by a(l,3)GalNAcT and a(l,3)GalT to 
produce blood group A and B antigens (respectively) is shown below in Figure 31. 
Figure 31 Biosynthesis of blood group antigens A and B by a(l,3)GalNAcT 
and a(l,3)GalT Lowary et al 1994
OH^OH 
O
HO OR
O
OH
F uca( 1,2)Galp-0-0cty 1
UDP-GalNAcand
a(l,3)GalNAcTA-transferase
UDP-Galand
a ( l ,3)GalTB-transferase
R == Octyl
HO
AcHN OR
O
O' OH
HOOH
GalNAca(l,3)Fuca(l,2)Galp-0-Octyl
O l^O H
l \ ^ 0  O H _O H  H O A , .^ ^
H O o OR
Gala(l ,3)Fuca(l,2)Galp-0-Octyl
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Each of the Fuca(l,3)Galp-0-0ctyl analogues were assessed by a radiochemical 
assay measuring the rate of transfer [^H]Gal or GalNAc, from the UDP-X parent. 
The results of the assay are shown below in Table 3.
Table 3 Relative acceptor activity (%) of disaccharide analogues using 
GalT A and B Lowaty et al 1993,1994
Substrate analogues *A transferase *B transferase
Unmodified disaccharide 1 0 0 1 0 0
3- Deoxy 0 0
4- Deoxy 0 . 1 0 . 2
6 - Deoxy 35 2 2
3- Methoxy 0.4 0
4- Methoxy 0.3 0
6 - Methoxy 13.4 3.2
3- Fluoro 0.3 0 . 1
4- Fluoro 0 0
6 - Fluoro 43 30
3- Amino 0 . 8 0 . 1
4- Amino 0 0.3
6 - Amino 4.7 2 . 0
No enzyme 0 0
*A11 substrates were used at concentrations of 2.5 pM for A transferase and 1.0 pM 
for B transferase.
In this example, Galp-O-Octyl substrate analogues are being tested as substrates of 
blood group A and B transferases.
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3.1.3 Radiochemical assay of Galp-O-Octyl analogues {Pereira et al 1995, 
Vetere et al 1996)
The radiochemical assay employed monitors the incorporation of lactose and 
results in the formation of anionic radiolabelled Neu5Ac*^GalGlc. This 
incorporation process shown below in Figure 21 (see Assay development, page 32).
Figure 21 Incorporation of [^ '*C} lactose
©NeuSAcGalGlc + * GalGlc
©Neu5Ac*GalGlc + GalGlc 
^Radiochemical isotope incorporation
In this assay (with no alternative substrate present), /raw^-sialidase will reversibly 
transfer sialic acid from sialyl lactose to lactose. The charged material can be 
separated from uncharged material by anion exchange chromatography as follows: 
The assay mixture is loaded onto A25 resin {Sigma Chemical Ltd) and washed with 
water to remove all non-sialylated material (wash). The resin is then eluted with 
N H 4O A C  (1 M) (eluent).
Since /ra«5 -sialidase is a reversible sialyl transferase (provided the 
substrate/acceptor concentrations are equal and an equilibrium is established) the 
total number of radioactive counts in wash and the eluent should be approximately 
equal, thus:
tram-smlidase 
and sialyl lactose
^lactose = *Wash ..........  — *Eluent = *sialyl lactose
* = [^^C]
If a better /raw^'-sialidase substrate is added to the assay to compete with [^ “^C] 
lactose, this will result m the unsialylated lactose being washed off the resin 
with H2O. Hence the radioactive counts in the eluent will be significantly smaller. 
In some cases the alternative substrate is unsuitable for trans-sialidase to sialylate, 
hence the radioactive result will mirror that of no substrate present. The graph below
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is a plot of the number of counts in the eluent divided by the total number of counts 
in each assay. In this representation, the lower the value, the better the substrate is. 
The higher figures indicate that some of the compounds compete with lactose for 
^ra«5 -sialidase but are not sialylated. Since the hydroxyl group at position 3 is 
paramount for a(2,3) sialyl coupling {Schenkman et al 1997), it was expected that 
any modifications to the 3-OH group would render the sugar a non-substrate. 
However, there was no information available regarding interactions of the hydroxyl 
groups at positions 4 and 6. Compounds l(i,ii,iii,iv)-3(i,ii,iii,iv) were 
radiochemically assayed and the results plotted (see experimental page 111), Figure 
32.
Figure 32 Graph of radiochemical assay of Galp-Octyl analogues
n
<N (N
Compounds 1 (i, ii,iii,iv)-3 (i,ii,iii,iv)
Legend of Figure 32
Legend Compound Legend Compound Legend Compound
l(i) 3H-Galp-Octyl 3(ii) 6 MeO-Galp-Octyl 2(iv) 4 NH2-Galp-Octyl
2(i) 4H-Galp-Octyl l(iii) 3F-Galp-Octyl 3(iv) 6 NH2-Galp-Octyl
3(1) 6 H-Galp-Octyl 2 (iii) 4F-Galp-Octyl No Sub No substrate
l(ii) 3 MeO-Gal p-Octy 1 3(iii) 6 F-Galp-Octyl No Enz No Enzyme
2(n) 4MeO-Galp-Octyl l(iv) 3 NH2-Galp-Octyl
Figure 32 indicates that indeed that trans-sialidase is not able to sialylate 
compounds l(i,ii,iii,iv). However /raw.y-sialidase is able to sialylate compounds 
2(i,ii,iii,iv), but only minimally. Surprisingly though, trans-sialidase is able to
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sialylate compounds 3(i,ii,iii,iv) easily. This plot gives an indication of trans- 
sialidase substrate specificity. This point is illustrated below in Figure 33A.
Figure 33A ^rans-sialidase substrate specificity with compounds l(i,ii,id>>v) -  
3 (i,ii,iü,M
OI^OH
HO
OH 
1 (i,ii,iii,iv)
X _OH OH_X
OH
2  (i,ii,iii,iv)
O ^  HO Octyl
O O-
OH
3 (l,ii,iii,iv)
'Octyl
/rawi'-sialidase 
and sialyl lactose
lactose
N o product Minimum HO 
product \
X (i) = H X (ii) = OMe
X (iii) = F X (iv) = NH2
COO O H . X
AcHN
HO HO
4 (i,ii,iii,iv)
OH Octyl
3.1.4 Potential sialylation of Galp-O-Octyl analogues l(i-iv)-3(i-iv) (monitored 
by T.L.C.)
Compounds l(i,ii,iü»iv) -  3(i,ii,iii,iv) (page 46) were incubated at 37"C with trans- 
sialidase (crude) and Neu5Ac-O-PNP. This was to assess the potential of 
compounds l(i,ii,iii,iv) -  3(i,ii,iii,iv) as substrates of /raw^-sialidase (see page 114 
for conditions). The results were monitored by T.L.C. As before, compounds 
3(i,ii,iii,iv) were all sialylated by ^ra«5-sialidase. The products of these incubations 
gave compounds 4(i,ii,iii,iv), which are reiterated below in Figure 33B .
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Figure 33B Compounds 4(i,ii,iii,iv)
OHNH HO OHOHHO CO; OH O
HO HOOH OH
4(ii)4(i)
NH;
/—^ ®NH; HO OH CO;OHHO
AcHNLj% 0(CH2)7CH3 HO OHOH
4(iv)4(1»)
The T.L.C. plate of substrates which gave sialylated products 4(i,ii,iii,iv)
were photographed and are shown below in Figure 33C.
Figure 33C Sialylation of Galp-O-Octyl substrates 3(i,ii,iii,iv)
6 cm
4(i,ii,iii,iv)
0 cm
10
Legend of Figure 33C (Minor product Rf values are not indicated)
Lane 1 Galp-Octyl Incubation, R f  =  0.8 l.an e 6  6 H Galp-Octyl marker, R f  =  0.8
Lane 2 Galp-Octyl marker, R f  =  0 .7 Lane 7 6 0 M e  Galp-Octyl Incubation, R f =  0.8, 0.5
Lane 3 6 F Galp-Octyl Incubation, R f =  0 .8 , 0.5 Lane 8  6 0 M e  Galp-Octyl marker, R f  =  0.8
Lane 4  6 F Galp-Octyl marker, R f  =  0.8 Lane 9 6 N H 2  Galp-Octyl Incubation, R f  =  0 .8 , 0.5
Lane 5 6 H Galp-Octyl Incubation, R f  =  0 .8 , 0.5 Lane 10 6 N H 2  Galp-Octyl marker, R f =  0.8
(In all cases, the marks at Rf = 0.4 and 0.1 are crude ^ram-sialidase)
This T.L.C. shows all of compounds 3(i,ii,iii,iv) have become sialylated producing a 
spot with an Rf = 0.5 (approx.). As suspected modification of the hydroxyl group at 
position three of Galp-O-Octyl, renders that attachment of sialic acid impossible and 
hence any modifications at that position render compounds l(i,ii,iii,iv) competitive 
non-sialylable substrates. Modification at the hydroxyl groups at position four 
allows the attachment of sialic acid at position three, however the turnover is 
minimal compared to the unmodified turnover at 50 %. Surprisingly, modification at 
the six position of galactose made no significant difference to the turnover and 
sialylation occurs readily. All of the above figures are approximate and based on a 
turnover assessment made by eye. This conclusion is illustrated below in Figure 
34.
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Figure 34 Approximate figures for the sialylation of Galp-O-Octyl
analogues (observed by eye from T.L.C.)
Approx, 50 %
H, F, OMe, NH2
(Parent Compound: 50 %)
Minimal turnover 
NH., F, OMe > H
HO Octyl
OH
No turnover
H, F,OMe,NH2 
3.1.5 Conclusions
Compounds l(i,ii,iii,iv) - 3(i,ii,iii,iv) {Lowary et al 1993) were assessed as potential 
rraw-sialidase substrates. The study was two fold, incorporating both a 
radiochemical assay {Pereira et al 1995, Vetere et al 1996) and an incubation with 
Neu5Ac-0-PNP followed by an assessment of sialylated products by T.L.C. The 
results of the radiochemical study indicate that (as expected) modification of the 
hydroxyl group at position 3 of the galactose analogues renders the sugar non- 
sialylatable. Modification to the hydroxyl group at 4 of the galactose analogues 
does not prevent sialylation, but the turnover is minimal. This indicates that the 
hydroxyl groups at positions 3 and 4 of the galactose analogues are significant to 
enzyme turnover. Modification to the hydroxyl group of position 6, surprisingly 
does not affect sialylation of galactose by traw^'-sialidase. This suggests that 
hydroxyl group at position 6 plays little or no role in enzyme binding. The 
radiochemical observations agree with the observations and assessment made by 
T.L.C. Since the hydroxyl group at position 6 may be modified, i.e. compounds 
3(i,ii,iii,iv) causing no significant loss of enzymatic turnover, it may be possible to 
exploit this property in synthetic oligosaccharide chemistry. For example, it may be 
possible to incorporate a solid phase linker (usually polymer beads) at the hydroxyl 
at position 6 to immobilise the galactose analogue. This method was pioneered in 
1963 by Bruce Merrifield for solid phase synthesis of polypeptides {Whittaker et al 
1996). The advantage of this approach is that the reactions will generally be driven 
to completion. Also the products can be isolated relatively easily by filtering off the
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insoluble support and then cleaving off the linker {Whittaker et al 1996). There are 
other examples of exploitation of /raw^'-sialidase in synthetic oligosaccharide 
chemistry, for example Paulson and Ito (1993) have exploited rmm-sialidase to 
create synthetic building blocks to assist in the synthesis of the sialylated 
ganglioside, GM4.
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3.2 Modified Galp(l,4)GlcNAcp-0-0ctyl library
A similar study to 3.1, was carried out on a library of modified Galp(l,4)GlcNAcp- 
O-Octyl sugars, obtained from Ole Hindsgaul’s laboratory, Alberta, Canada. These 
Galp(l,4)GlcNAcp-0-0ctyl analogues were originally synthesised as potential 
inhibitors of a-(l,3)galactosyltransferase. Figure 35 shows glycosylation which is 
catalysed by a-(l,3)galactosyltransferase (obtained from calf thymus).
Figure 35 a-(l,3)gaiactosyltransferase catalysed synthesis of Gala(l,3)Galp 
(l,4)pGlcNAc-OR {Palcic et al 1998)
G a lp (l,4 )G lc N A c -0 R
U D P -G al 
a -(  1,3)G alactosyItransferase  
R = Octyl
G a la ( l ,3 )G a lp ( l ,4 )G lc N A o O R  
Galp(l,4)GlcNAcp-0-0ctyl analogues [compounds 5(i,ii,iii,iv)-10(i,ii,iii,iv)], Figure 
36) were synthesised enzymatically. These analogues were modified at the two 
prime, three prime, four prime, six prime, three and six hydroxyl groups in turn with 
four substituents. In each case a hydroxyl group was replaced with either an acid, 
amine, amide or guanidino group. These modifications are illustrated below in 
Figure 36, compounds 5(i,ii,iii,iv)-10(i,ii,iii,iv).
Figure 36 24 Galp(l,4)GlcNAcp-0-0ctyl analogues {Hindsgaul et al 1996)
OH^OH HOt- ^ ^ ^ o (CH2)7CH3
R OH
NHAcR .OHHo S ^ o S ^ O ( C H 2 ) 7 C H 3
OH OH
9M-OH D NHAc H or::^o5Z^o(C H ,),cH 3
OH OH
?*^OH NHAc
rS ^ oS ^ O ( C H 2 ) 7 C H 3
OH OH
6(UUii,iv)
NHAc 
OH OH
l'^OH NHAcHor:%^o2Z^o(CH2)7CH3
OH R
10(MMii,iv)
R = (0
NHz 01
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Compounds [except were radiochemically
assayed using a disaccharide analogue (10.8 nM), UDP-[6-^H]Gal (100,000 DPM), 
enzyme solution and assay buffers to make a final volume of 20 gl. They were 
assayed at 37 ®C for 30 mins. Shown below if Figure 37 is a table illustrating the 
relative rate of glycosylation using a-(l,3)GalT.
Figure 37
1998)
a-(l,3)GalT catalysed glycosylation relative rate {Palcic et al
Galp(l,4)GlcNAcp-0-0ctyl analogues R"
Relative 
rate* (%)
NHAc
OH OH 9(i,ii,iii,iv)
OCHgCHgNHg OCHzCOoH 
OCH2CONH2, 0 CH2C=NH2 CrNHz
< 1 
<  1 < 1 
<  1
Y'^OH NHAc
OH 10(i,ii,iii,iv)
OCH2CH2NH2OCH2CO2H
OCHzCONHz^OCH2 C=NH2 CI NH2
1154To
Y'^OH NHAc 
h o S ^ o ' ! S Ç : ^ ^ o ( c h . ) 7 C H 3
6(l,li,iii,lv)
OCH2CH2NH2OCH2CO2H
OCHzCONHz^
OCH2C=NH2^CrNH2
5
1
1
1
*L HO NHAc
OH OH 7(i,ii,iii,iv)
OCH2CH2NH2 OCH2CO2H 
OCH2CON Hz .
OCHz C=NHz Cl'NHz
1 
<  1 
<  1 
<  1
HO NHAc
8(i,ii,iii,iv)
OCH2CH2NH2
OCH2CO2H
OCHzCONHz^OCHz C=NHz Cl'NHz
2 0775
* The concentration of each analogue = 540 pM
3.2.2 Modified Galp(l,4)GlcNAcp-0-0ctyl radiochemical assay
Compounds 5(i,ii,iii,iv)-10(i,ii,iii,iv) (shown before m Figure 36) were incubated 
and assessed radiochemically as before, see page 46 and page 111 {Pereira et al 
1995, Vetere et al 1996). The results were tabulated and plotted, Figure 38. These 
plots represent the result of the radiochemical assay using alternative substrate 
[compounds 5(i,ii,iii,iv)-10(i,ii,iii,iv)] to lactose. The results of the screen of 
compounds 5(1,ii,iii,iv)-10(i,ii,iii,iv) may be interpreted as before, i.e. compounds
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giving results with values between 0-15 % Elution/Total (DPM) are good trans- 
sialidase substrates.
Figure 38 The four graphs of radiochemical assay of compounds 5(i,ii,i:i,:v)- 
10(i,ii,iii,iv)
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Legend of Figure 38
Legend Compound Legend Compound
5(i) 2’Amine-Gaip( 1,4)GlcN AcP-O-Octyl 5(ii) 2’Acid-Gaip(I,4)GlcNAcP-0-0ctyl
6(i) 3 ’ Amine-Gaip( 1,4)GlcN AcP-O-Octyl 6(ii) 3’Acid-Gaip( l,4)GlcNAcP-0-0ctyl
7(0 4 ’Amine-GaiP( 1,4)GlcN AcP-O-Octyl 7(i0 4’Acid-Gaip(l,4)GlcNAcP-0-0ctyl
8(i) 6’Amine-GaiP( 1,4)GlcN AcP-O-Octyl 8(i0 6’Acid-GaiP( 1,4)GlcN AcP-O-Octyl
9(i) 3Amine-Gaip( 1,4)GicN AcP-O-Octyl 9(ii) 3Acid-GaiP( 1,4)GlcN AcP-O-Octyl
10(0 6Amine-Gaip( 1,4)GlcN AcP-O-Octyl 10(iO 6Acid-Gaip( 1,4)GlcN AcP-O-Octyl
No Sub No substrate No Sub No substrate
No Enz No enzyme No Enz No enzyme
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Legend of Figure 38 cont.
Legend Compound Legend Compound
5(iii) 2’Ainide-Gaip( 1,4)GlcNAcP-0-0ctyl 5(iv) 2’Guaii.-Galp( 1,4)GlcN AcP-O-Octyl
6(iii) 3 ’ Amide-Gaip( 1,4)GlcNAcp-0-0clyl 6(iv) 3 ’Guan.-Galp(l ,4)GlcN Acp-O-Octyl
7{iii) 4’Amide-Gaip{ 1,4)GlcNAcP-0-0ctyl 7(iv) 4’Guan.-Gaip( 1,4)GlcNAcP-0-0ctyl
8(iii) 6 ’ Amide-Galp( 1,4)GlcNAcP-0-0ctyl 8{iv) 6 ’Guan.-Gaip( 1,4)GlcNAcP-0-Octyl
9(iii) 3 Amide-GaiP( 1,4)GlcNAcP-0-0ctyl 9(iv) 3Guan.-Gal P( 1,4)GlcN AcP-O-Octyl
lO(iii) 6 Amide-Gaip{ 1,4)GlcNAcP-0-0ctyl lO(iv) 6Guan.-Galp(l,4)GlcNAcp-0-0ctyl
No Sub No substrate No Sub No substrate
No Enz No enzyme No Enz No enzyme
This study indicates that compounds 8(i,ii,iii,iv), 9(i,ii,iii,iv) and 10(i,ii,iii,iv) can be 
sialylated by /ram-sialidase (as expected), but that compounds 5(i,ii,iii,iv), 
6(i,ii,iii,iv) and 7(i,ii,iii,iv) are non-sialylable substrates. Compounds ll(i,ii,iii,iv)- 
13(i,ii,iii,iv), the sialylation products of compounds 8(i,ii,iii,iv), 9(i,ii,iii,iv) and 
10(i,ii,iii,iv) are shown below in Figure 39A.
Figure 39A Sialylation products of compounds 8(i,ii,iii,iv), 9(i,ii,iii,iv) and 
10(i,ii»iii,iv)
rm«5-sialidase
8(i,ii,ili,iv) -------------------- AcHN
HO HO
u o  NHAc
11(Mr,iri.iv)
HO OH
^ra«5-sialidase
AcHN.
PH-OH
HO HO
NHAc0 (CH2)7CH3
OH OH
12(i,il,ill,lv)
HO OH
^ra«5-sialidase
AcHN 
HO HO
OH NHAc
O H07-^.4t--7-o(GH2)7CH3
13(1,II,m, IV)
R =  (i) N H 2  ( i i ) =  / ' - - y O H  
O
NH
O NH® 01®
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3.2.3 Potential sialylation of compounds 5(i,ii,iii,iv)-10(i,ii,iii,iv) using NeuSAc- 
O-PNP (monitored by T.L.C.)
Compounds 5(i,ii,iii,iv)-10(i,ii,iii,iv) Figure 36, page 55, were incubated at 37 °C 
overnight (approx. 16 hours) with Neu5Ac-0-PNP and ^raw^-sialidase (crude), see 
page 114. The results were recorded by T.L.C. and photographed. An example of 
sialylation of compounds 10(i,ii,iii,iv) to give 1 l(i,ii,iii,iv) is shown below in Figure 
39B.
Figure 39B Compounds ll(i,ii,iii,iv)
I #
1 2
Legend of Figure 39B
3 4 5 6
I.ane 1 10(i) Incubation, R f  =  0 .6 , 0.5 I .anc 4 lO(lv) Incubation, R f  =  0.6 , 0.4
Ivane 2 10(11) Incubation, R f  =  0.6, 0 .4 Lane 5 G aIp (l,4 )G Icp -0-0ctyI Incubation. R f =  0.7, 0 .6
Lane 3 10(111) Incubation, R f = 0 .6 ,  0.5 Lane 6 G aIp(I,4)G Icp-0-0ctyI marker, R f = 0 .7
(Only the significant spots are referenced)
This T.L.C. shows all of compounds 8(i,ii,iii,iv) have become sialylated producing a
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spot with an Rf = 0.5 and 0.4 (approx.). As before modification of the hydroxyl 
group at position three prime of this sugar renders attachment of sialic acid 
impossible and hence any modifications at this position render compounds 
6(i,ii,iii,iv) non-sialylatable substrates. Modification to the hydroxyl groups at 
position two prime and four prime again allow the attachment of sialic acid at 
position three prime, however the turnover is minimal compared to the unmodified 
turnover at 50 %. Modification of hydroxyl groups at the six prime position of 
Galp(l,4)GlcNAcp-0-0ctyl made no significant difference to the turnover, 
concurrent with the results of the radioactive screen and the study Galp-O-Octyl 
[compounds 3(i,ii,iii,iv)]. Modification of the hydroxyl groups at position three and 
six is also tolerated. This relative toleration of substrate modifications of trans- 
sialidase can be compared to the lack of substrate modifications permitted by 
a(l,3)GalT (page 56). trans-sialidase substrate specificity to compounds 
5(i,ii,ii,iv)-10(i,ii,iii,iv) is illustrated below in Figure 40.
Figure 40 Approximate figures of turnover for ^raifs-sialidase product 
formation from Galp(l,4)GlcNAcp-0-0ctyi analogues (assessment made by eye)
Approx. 50 % Turnover
Minimal Turnover Approx. 50 % Turnover
V
Minimal Turnover Approx. 50 % Turnover
3.2.4 Conclusions
The results of the radiochemical assay indicates that modification of the hydroxyl 
groups at positions 2 \  3’, 4’ (compounds 5(i,ii,ii,iv)-7 (i,ii,iii,iv) {Hindsgaul et al 
1996)) prevents or prohibits the attachment of sialic acid to Galp(l,4)GlcNAcp-O- 
Octyl. This information reiterates previous findings and indicates that the hydroxyl 
groups at positions 2’, 3’ and 4’ of Galp(l,4)GlcNAcp-0-0ctyl are paramount for
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/  NHAc I
OH i
No Turnover
sialylation. Modification of the hydroxyl groups at positions 6 ’, 3 and 6  (compounds 
8(i,ii,ii,iv)-10(i,ii,iii,iv) {Hindsgaul et al 1996)) play a minimal or no role in the 
enzyme binding and subsequent sialylation. These findings are comparable with the 
results of ^ raw '^-sialidase incubations (with Neu5 Ac-O-PNP) which were assessed by 
T.L.C., agreeing with previous findings. It may be that the hydroxyl group at the six 
prime position (position six of galactose) is projecting into space and hence is too far 
from the binding site to be of consequence. As before it may be possible to 
incorporate a solid phase linker {Whittaker et al 1996) at the 6  prime position to 
immobilise Galp(l,4)GlcNAcp-O-Octyl analogues for exploitation of ^ ra«5-sialidase 
in organic synthesis. /ra«5'-Sialidase can also tolerate modifications to the hydroxyl 
groups at position 3 and 6  the disaccharide unit. This point is shown 
diagrammatically again in Figure 41.
Figure 41 Diagrammatic representation of key positions required for 
sialylation by ^raifs-sialidase
Minimal turnover
OH
OHHO
OH
No turnover
Minimal turnover
Xj = Any substrate of Galp( 1,4)GlcNAcp-0-0ctyl/Galp-0-0ctyl screen 
X2/X3 = Any substrate of Galp ( 1,4)GlcNAcp -O-Octylscreen
61
Chapter 4
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Chapter 4 - Introduction
4.1 Trypanosoma cruzi G-strain (Epimastigotes)
To understand fully the actions of Trypanosoma cruzi (G-strain) /rawi'-sialidase it is 
necessary to characterise the cell surface glycoconjugates. This allows an 
extrapolation to the role of carbohydrates on the parasitic cell surface. The cell 
surface glycoconjugates from the epimastigote form of Trypanosoma cruzi have 
been analysed by SDS-PAGE. The result of this was a broad band at 38-43 kDa 
{Previato et al 1994). These components are non-sialylated. The oligosaccharide 
cell surface acceptor moiety of T. cruzi (G-strain) consists of GlcNAc units which 
other oligosaccharides can be joined to give branched structures and are O- 
glycosidically bonded to the amino acids serine or threonine {Previato et al 1994).
4.1.2 Characterisation of the oligosaccharides accepting sialic acid
Analysis of the isolated epimastigote showed neutral sugars 57.5 %, hexosamine 16 
%, protein 4.5 %, phosphorus 1 %, sialic acid - trace. The sugar region was then 
digested to reveal the monomers present as follows, galactose 4.8 M, A-acetyl 
glucosamine 1.6 M, mannose 1 M and glucose 0.15 M, (relative molarity) {Previato 
et al 1994). The cell surface glycoproteins were subject to enzymatic digestion and 
then separated on a Bio-Gel P4 column. This purification gave five oligosaccharide 
fractions {Previato et al 1994). The structures of these fragments were then analysed 
and evaluated using F.A.B.-MS and G.C. This study revealed the oligosaccharides 
which are shown in Figure 42 {Previato et al 1994).
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Figure 42 O-Glycosidically linked GlcNAc-bound oligosaccharides isolated 
from 38/43 kDa glycoproteins from epimastigote T. cruzi (G-strain) {Previato et 
al 1994).
Oligosaccharide Structure
Disaccharide-alditol
T risaccharide-alditol
T etrasaccharide-alditol
p-Gal/^(l— 4)
p-Galp(l—^ 6) 
p-Gal/^(l—► 4)
p~Gal/?( l—*^3)—p-Galp(l-*" 6)
p-Gal/^(l—► 4)
p-Galp(l-^3)
p-Galp(l-»^2)
^ -G a lp ( l-^  6)
GlcNAc-ol
GlcNAc-ol
GlcNAc-ol
Pentasaccharide-alditol
p-Galp(l-
p-Galp(l-
p-Ga(p(l-
-2)-p-Gal/-(l 
-3)
2^)
^ -G alp (l-
4)
-6)
GlcNAc-ol
These fragments are the main acceptors of neuiaminic acid on the cell surface of T. 
cruzi (G-strain). They are unusual in that it was suspected that the branched sugar 
moieties would be O-linked to GalNAc and not GlcNAc, since only unsubstituted O- 
linked GlcNAc’s had been discovered previously {Previato et al 1994). It is 
suspected that monosaccharide O-GlcNAc’s have an important role in the cellular 
pathway regulation. Single O-GlcNAc oligosaccharides have also been located in 
Trypanosoma brucei {Haltiwanger et al 1992) as well as other parasitic organisms. 
The GlcNAc end of these units can also be attached to other residues forming three 
to six units. It is the other end of the chains which give a negative charge (i.e. sialic 
acid) which is recognised by antibodies and lectins. Sialylated epitopes (Ssp3) are 
important for monoclonal antibody recognition {Frasch et al 1996), cell surface 
attachment and invasion by T. cruzi. Metacyclic trypomastigotes use a sialylated
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glycoprotein (35/50 kDa by SDS-page), to invade cells, presumably by an analogous 
method {Previato et al 1994).
The O-GlcNAc units of T. cruzi G-strain are novel since some consist of 
branched structures carrying both galactofuranose (Gal-/) and galactopyranose (Gal- 
p) substitutions {Previato et al 1994).
4.1.3 Trypanosoma cruzi (Y-strain)
Analysis was carried out on p-eliminated oligosaccharide-alditoIs. The glycoprotein 
was reduced using sodium borohydride before separation took place on a Bio-gel P4 
column {Previato et al 1995). Foui' fractions were collected, similar to that of 
Trypanosoma cruzi G-strain. The fom' fractions were characterised and named as 
Fractions I, II, IB and IV (0.3, 5.0, 3.0 and 0.4 relative molar ratio) {Previato et al
1995). These fractions were characterised by G.C. and NMR spectroscopy. Fraction 
I consists of GlcNAc only whereas Fractions II, III and IV comprised of a mixture of 
GlcNAc-ol, galactose and GaUSfAc-ol, and each had mono, di and trisaccharides 
present {Previato et al 1995), see Figure 43.
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Figure 43 The structures of the O-linked oligosaccharides found in 
Trypanosoma cruzi Y-strain {Previato et al 1995)
Oligosaccharide
Monosaccharide-alditol
Disaccharide-alditol
T risacchaiide-alditol
Structure 
^-Ga\p{\-*' 3) — GlcNAc-ol 
p-Galp(l—*^4) — GlcNAc-ol
p-Gal/?(l—^ 3)
GlcNAc-ol
GlcNAc-ol
P-Gal/?(1—►ô) 
p-Galp(l~^4) 
p-G alp(l-^6)'^
p-G alM l-^3).
p-Galp(l-^2)—p-Galp(l—►h) " 
p-Gal/7-(l—^ 4)
p-Galjp(l—^ 2)— p-Galp(l-^6)
GlcNAc-ol
GlcNAc-ol
Based on these natural fragments, known to be the sites of sialic acid recognition, a 
variety of disaccharides and trisaccharides have been synthesised, some are shown 
below Figure 44 {Kartha and Field 1997).
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Figure 44 A variety of potential disaccharide and trisaccharide substrates 
for T. cruzi ^r«/iv-sialidase {Kartha and Field 1997) (The circles indicate the 
potential sites of sialic acid attachment)
OH 
O
HO OMe
OO H o y
Galp(l,2)Galp-0-Me (14)
OI-L-OH
OMe
HO^H
Glcp(U2)Galp-G-Me (15)
OH^OH OH OH O H _O H
OMe (H
OH OH
OH
•O-Octyl
Galp(l,3)Galp-0-M e(16) 
•OH
HO _ 0
OH NHAc
Galp(l,3)GlcNAcp-0-0ctyl (17) 
(HO)
OH
(H g-V --v^-'O M e 
OH
Galp(l,6)Galp-0-Me (18)
HO 
HO
HO
OH SiMea
O H _.n
Galp(l,6)Galp-0-CH2CH2SiMe3 (19)
OH^OH
O-Octyl 
OH
Glcp(l,6)Galp-0-0ctyl (20) 
HO OH HO
OH HO-
Galp(l,4)Glc (21) (lactose)
O-Octyl
OI^OH ^O H
OH
Galactose (23)
OH
OH
G lucose(24)
Galp(l ,4)plcp-0-Octyl 
Galp(l,6) (22) 67
Chapter 4 -  Results and Discussion
4.2 Radiochemical assay of all the Galp(l,X)Gal derivatives
The Galp(l,X)Gal derivatives were assayed radiochemically, as before see page 46 
and 111 {Pereira et al 1995, Vetere et al 1996) to assess their capability as trans- 
sialidase substrates. The results were plotted and are shown below in Figure 45.
Figure 45 % E/Total (DPM) of all Galp(l,X)Gal
25-
20 -
es
00
Galp(l^)Gal Substrates
Legend of Figure 45
Galp(l,2)Galp-0-Me (14) Galp(l,4)[Galp(l,6)Glc] p-O-Octyl (21)
Glcp(l,2)Galp-0-Me(15) Galp(l,4)Glc (22)
Galp(l,3)Galp-0-Me(16) Galactose (23)
Galp( 1,3)GlcNAcp-O-Octyl (17) Glucose (24)
Galp(l,6)Galp-0-Me (18) No inhibitor
Galp(l,6)Galp-0-CH2CH2SiMc3 (19) No enzyme
Glcp(l,6)Galp-0-0ctyl (20)
The plotted results above are based on an average of three radioactive assays for all 
substrates, except for compounds (15) and (19) which are based on an average of 
four radioactive assays. The results above are an indication of the oligosaccharides 
which are good substrates of /r«w.y-sialidase, (Compounds giving results with values 
between 0-15 % Elution/Total (DPM) are good trans-svàXidosQ substrates). As 
expected glucose is not a substrate.
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4.3 Multi-sialylation of oligosaccharide containing resin
It is apparent from the radioactive assay, page 68 that it may be possible to sialylate 
an internal galactose. It may also be possible to sialylate more than one p-galactose 
moiety, i.e. a terminal galactose as well as an internal galactose (depending of the 
Galp(l,X) linkage). It is believed that ^rara-sialidase has two galactose binding sites 
(one in the active site and one in the lectin binding domain, compare to 
Micromonospora Viridifaciens neuraminidase), it may be possible to simultaneously 
bind two p-galactose moieties. Consequently, this theory was tested using a resin 
containing many surface galacto-pyranosides was purchased {Sigma Chemicals Ltd). 
The resin, /?-aminobenzyl-l-thio-p-S-galacto-pyranoside was used as a potential 
acceptor substrate and assayed radiochemically as before. The initial study gave a 
result suggesting that this resin is comparable with other reliable substrates of trans- 
sialidase from our study, such as Galp(l,3)GlcNAcp-0-0ctyl and Galp(l,6)Gal. 
Therefore, a study was carried out radiochemically on this resin using a serial 
dilution. Figure 46 shows a plot of the serial dilution of p-aminobenzyl-l-thio-p-S- 
galacto-pyranoside.
Figure 46 p-aminobenzyl-l-thio-p-S-galacto-pyranoside (substrate) resin
(serial dilution)
I
4540
3530
2520
15
10
50
>
>
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Substrate Concentration
This graph indicates that p-aminobenzyl-l-thio-p-S-galacto-pyranoside is a good 
substrate of  ^ ra«5-sialidase.
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The binding capacity of the resin was calculated as follows:
1ml of resin binds 2 mgs of (3-galactosidase (Moleculai* weight of p-galactosidase, 
monomer {E. coif) =116 kDa) 1 ml of resin will bind 1.72 xlO'* mol of protem. 
Assuming a ratio of 1 sugar/ 1 enzyme 1 ml resin contains 1.72 xlO'® mol sugar.
.'. 1 ml/200|il s  86 gM, 1 ml/2ml = 8.6 |xM, 1 ml/20ml = 0.86 pM 
The above data for /7-aminobenzyl-l-thio-p-O-galacto-pyranoside resin was re­
plotted to assist the calculation for an IC50 value for this substrate. This plot is 
shown below in Figure 47.
Figure 47 Concentration of p-aminobenzyl-l-thio-p-S-galacto-pyranoside 
versus % inhibition
60 -§
a
20 -
10 0 O.I
[SljLiM
This plot indicates that p-aminobenzyl-l-thio-p-S-galacto-pyranoside has IC50 value 
of 34 pM.
4.4 /m/f5-Sialidase catalysed sialylation of di and trisaccharide acceptor 
substrates
Compounds (14)-(24), Figure 44, page 67, were incubated at 37 °C overnight 
(approx. 16 hours) with Neu5 Ac-O-PNP and tram-sialidase (crude). The results 
were recorded on T.L.C. and photographed.
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4.4.1 Incubation of GaIp(l,2)Gal-0-Me (14), Glcp(l,2)GaIp-0-Me (15) and 
Galp(l,3)Galp-OMe (16)
Galp(l,2)Galp-0-Me, Glcp(l,2)Galp-0-Me and Galp(l,3)Galp-0-Me were incubated 
as before, also see page 114. Figure 48 shows the photograph of the T.L.C. plate. 
This photograph shows that Galp(l,3)Galp-0-Me and Galp(l,2)Galp-0-Me have 
been sialylated but Glcp(l,2)Gal-0-Me has not. Strong marker solutions show some 
degradation on storage, although all were purified before experimentation.
Figure 48 Sialylation of Galp(l,2)GaI-0-Me, Glcp(l,2)Galp-0-Me and 
Galp(l,3)Galp-OMe
# #  #
1 2 3 4 5 6
Legend of Figure 48 (Only Rfs corresponding to the main compound are indicated)
Lane 1 Incubation o f  Gaip( I ,3 )G a ip -0 -M e with 
traiw-siaiidase, R f  =  0.4, 0.3
Lane 4 G IcP (I,2 )G aIp -0-M e marker, R f  =  0 .4
Lane 2 G a ip (l,3 )G a ip -0 -M e marker, R f  =  0 .4 Lane 5 Incubation o fG a Ip (l,2 )G a ip -0 -M e  with  
trans-sialidase. R f =  0.4, 0.3
I vane 3 Incubation o f  GIcP( 1 ,2 )G aip -0 -M e with  
/ram -sia lidase. R f  =  0.4
Ivane6 G aip (I,2 )G aIp -0-M e, R f = 0 .4
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4.4.2 Incubation of GaIp(l,6)Galp-0-Me (18), Galp(l,6)Galp-0-CH2CH2SiMc3 
(19) and GIcp(l,6)Galp-0-0ctyl (20)
A similar experiment was carried out using Galp(l,6)Galp-0-CH2CH2SiMe3, 
Glcp(l,6)Galp-0-0ctyl and Galp(l,6)Galp-0-Me as /raw.s'-sialidase acceptors. 
Figure 49 shows the photograph of the T.L.C. plate. This photograph confirms that 
Galp(l,6)Galp-0-CH2CH2SiMe3, Glcp(l,6)Galp-0-0ctyl and Galp(l,6)Galp-0-Me 
have been sialylated. Strong maiker solutions show some degradation on storage, 
although all were purified before experimentation.
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Figure 49 Sialylation of Galp(l,6)Galp-0-CH2CH2Si(CH3)3, Glcp(l,6)Galp- 
O-Octyl and Galp(l,6)Galp-0-Me
8 cm
m
1 1
1 2 3 4 5 6 7 8
Legend of Figure 49 (Only Rfs of the main compounds are indicated)
Lane 1 G aip(l,6)G aip-0-C H 2C H 2Si(C H 3)3 marker, 
R f = 0 .5
Lane 5 G aip (I,6 )G aIp -0 -M e, R f  =  0.3
Lane 2 Incubation ofG aiP (I,6 )G aip -0-C H 2C H 2Si-  
(C H 3 ) 3  with trarts-sialidase, R f  =  0 .5 , 0.3
Lane 6  Incubation o f  G a ip (I ,6 )G a ip -0 -M e with trans- 
sialidase, R f  =  0.3, O.I
Lane 3 G IcP(I,6)G aip-0-O ctyI marker, R f  =  0 .5 Lane 7 Incubation lactose with trans-sialidase. R f =  
0.4 , 0.2
Lane 4 Incubation o f  GIcP( l,6 )G a Ip -0 -0 c ty I  w ith  
trans-sialidase. R f =  0.5, 0 .4
Lane 8 Sialyl lactose marker, R f  =  0.2
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4.4.3 Incubation of Glcp(l,6)GaIp-0-0cty! (20) and Galp(l,4)[Galp(l,6)Glc]p- 
O-Octyl (21)
The disaccharide Glcp(l,6)Galp-0-0ctyl was incubated as before, in parallel with 
the incubation of a branched trisaccharide, Galp(l,4)[Galp(l,6)Glc]p-Octyl {Kartha 
and Field 1997). The incubation of Glcp(l,6)Galp-0-0ctyl is important since the 
terminal residue is glucose and not galactose, as in all of the previous substrates. 
Figure 50 shows a photograph of the T.L.C. plate of this incubation. This 
incubation was carried out using two concentrations of Neu5 Ac-O-PNP, (see legend 
below for concentrations).
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Figure 50 Sialylation of Galp(l,4)[Galp(l,6)Glc]p-0-0ctyl and
Glcp(l,6)Galp-0-0ctyl
9.5 cm
0 cm
t
•  •  m
# # # 4 #  ^
- % ^ '?  V
Legend of Figure 50
Lane 1 Incubation o f  branched lactose (3 0  mM  
N eu 5 A c-0 -P N P ), R f  =  0 .6 , 0.5
Lane 4  Ineubation o f  GIcP( I ,6 )G a ip -0 -0 cty I (3 0  mM  
N eu 5 A e-0 -P N P ), R f =  0. 7, 0.4
Ivane 2 Ineubation o f  branched lactose (1 0  mM  
N eu 5 A e-0 -P N P ), R f  =  0 .6 , 0.5
Lane 5 Incubation o f  G Icp (I,6 )G aIp -0 -0ctyI (10  mM  
N eu 5 A c-0 -P N P ), R f  =  0 .7 , 0.4
Lane 3 branched lactose marker, R f=  0 .6 Lane 6 G Ie p (I,6 )G a Ip -0 -0 cty l marker, R f  =  0 .7 , 0 .4
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4.5 Sialylation of Galp(l,6)Galp-0-CH2CH2SiMe3 (19)
In an attempt to confiim the sialylation of these Galp(l,X)Gal substrates, three of the 
substrates, Galp( 1,6 )Galp-0 -CH2CH2SiMe3, Galp( 1,4)[Galp( 1,6)]Glcp-0-0ctyl and 
Glcp(l,6)Galp-0-0ctyl were incubated on a preparative scale. Sialylated products of 
these incubations were analysed by electiospray-MS. Neu5Aca(2,3)Galp(l,6)Galp- 
0 -CH2CH2SiMe3 and Neu5Aca(2,3)Glcp(l,6)Galp-0-Octyl were also degraded with 
C. perfringens neuraminidase, p-galactosidase and p-glucosidase respectively.
4.5.2 Preparative scale sialylation of Galp(l,6)Galp-0-CH2CH2SiMe3 (19)
Galp(l,6 )Galp-0 "CH2CH2SiMe3 was synthesised chemically {Kartha and Field
1996). In an attempt to prove the sialylation of this oligosaccharide, already 
confirmed radiochemically and by T.L.C., the incubation of Galp(l,6)Galp-0- 
CH2CH2SM c3 was increased to a preparative level of approximately 3 mgs. As 
before, the sialylation of (19) by r^«w5 -sialidase is reversible with the sialylated 
product bemg a substrate for the back reaction. Figure 51 illustrates the proposed 
sialylation of Galp(l,6 )Galp-0 -CH2CH2SiMe3. A product (approximately 1 mg) was 
isolated which had the correct assumed Rf value by T.L.C.
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Figure 51 /r«#fs-SiaIidase sialylation of Galp(l,6)Galp-0-CH2CH2SiMe3
AcHN OPNP
HO
Neu5 Ac-O-PNP
fraw.s'-sialidase
SiMe*:
AcHN
Galp(l,6)Galp-0-CH2CH2SiMe3 (19)
Another possible 
point of sialylation
% .
A c H N < % Z 0 y - 0 . \ . - ^ ^
HO /
O.
SiMoq
HO OH
SiMe-:
B
Another possible 
point of sialylation
Neu5 Aca(2,3)Galp(l ,6)Galp-0-CH2CH2SiMe3 (25)
There is two possible sites of sialylation on the Galp(l,6)Galp-0-CH2CH2SiMe3 as 
indicated on Figure 51. Consequently there are two possible products from this 
trflW5-sialidase incubation. The two products are shown above as product A and B. 
A is the most likely based on previous literature {Schenkman and Vandkerchove 
1992). However, product B is also a viable proposition which will be discussed 
later.
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4.5.3 Characterisation of Neu5Aca(2,3)Galp(l,6)Galp-0-CH2CH2Si(CH3)3 (25) 
- Electrospray Mass Spectrometry
Neu5Aca(2,3)[Galp(l,6)GaIp-0-CH2CH2Si(CH3)3] was isolated and subject to 
Electro spray Mass Spectrometry. The spectrum is shown below in Figure 52. The 
spectrum was run from 510-900 Da/e. The calculated molecular weight for this 
compound is 732.78. The spectrum shows clearly only one peak at 732.82 Da/e.
Figure 52 Mass 
CH2CH2Si(CH3)3
Spectrum of Neu5Aca(2,3)Galp(l,6)Galp-0-
Scm ES-
570 54
520 540 560 580 600 620 640 660 680 700 720 740 760 780 800 820 840 860 880 900
4.5.4 Enzymatic digestion of Neu5Aca(2,3)Galp(l,6)Gaip-0-CH2CH2SiMe3
(25) Neu5Aca(2,3)Galp(l,6)Galp-0-CH2CH2SiMe3 was subjected to systematic 
enzymatic digestion with p-galactosidase and C perfringens neuraminidase. Shown 
below in Figure 53 is the photograph of the enzymatic digestion of 
Neu5Aca(2,3)Galp(l,6)Galp-0-CH2CH2SiMe3.
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Figure 53 Systematic enzymatic digestion Neu5Aca(2,3)Galp(l,6)Galp-0-
CHzCHzSiMea (25)
0 cm
âÊk9
1 2 3 4 5 6 7 8 9 10 11 12
Legend of Figure 53
I^ane 1 C, perfringens  neuram inidase Marker, R f  =  0 Lane 7 Incubation c, N eu 5 A ca (2 ,3 )G a lp (l,6 )G a lp -0 -  
CH 2CH 2 Si(C H 3 )3  w ith C. perfr in gen s  neuraminidase, 
R f =  0.5
Lane 2 P-galactosidase Marker, R f  =  0 Lane 8 Incubation d, G a lp (l,6 )G a lp -0 -  
C H 2CH 2 Si(C H 3 ) 3  w ith  C. perfringens  neuraminidase. 
R f = 0 .5
Lane 3 Neuram inic acid Marker, R f  =0 Lane 9 Incubation e, N eu 5 A ca (2 ,3 )G a iP (l,6 )G a lp -0 -  
CH 2C H 2Si(C H 3 )3  w ith  C  p erfringens  neuraminidase 
and P-galactosidase, R f =  0.2
Lane 4 G alactose Marker, R f  =0.2 Lane 10 Incubation f, N eu 5 A ca (2 ,3 )G a lp (l,6 )G a ip -  
0-CH2CH2Si(CH3)3 and buffer only, R f  =  0 .5 , 0.3
l^ n e  5 Incubation a, N eu 5 A ca (2 ,3 )G a ip (l,6 )G a ip -  
0-CH2CH2Si(CH3)3 w ith P -galactosidase, R f  =  0.3
Lane II N eu 5 A ca (2 ,3 )G a lp (I,6 )G a ip -0 -  
CH 2CH 2 Si(C H 3 ) 3  Marker, R f  =  0.3
Lane 6 Incubation b, G a lp (l,6 )G a lp -0 -  
CH 2CH 2 Si(C H 3 ) 3  w ith P-galactosidase. R f  =  0.2
Lane 12 Galp(1,6)G alp-0-CH 2CH 2Si(CH 3)3M arker, 
R f = 0 .6 ,  0 .5 , 0.1
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4.5.5 Systematic degradation of Neu5Aca(2,3)Galp(l,6)Galp-0-CH2CH2SiMe3
(25)
Neu5Aca(2,3)Galp(l,6)Galp-0-CH2CH2SiMe3 is not subject to hydrolysis by p- 
galactosidase (E. coli). This is because the Neu5Ac is blocking the enzyme from 
cleaving the galactose residue and hence the trisaccharide cannot be digested. 
Cleavage of Galp(l,6)Galp-0-CH2CH2SiMe3 by p-galactosidase (E. coli) shows the 
presence of galactose.
Treatment of the sialylated material, Neu5Aca(2,3)Galp(l,6)Galp-0-CH2CH2SiMe3, 
by C. perfringens neuraminidase yields Galp(l,6)Galp-0-CH2CH2SiMe3 as 
expected, from the removal of Neu5Ac, however neuraminidase has no affect on 
Galp(l,6)Galp-0-CH2CH2SiMc3. Only after the sialic acid is cleaved fron Neu5Ac-X 
by C. perfringens neuraminidase then is it possible for the p-galactosidase to cleave 
Galp(l ,6)Galp-0-CH2CH2SiMe3.
Shown below in Figure 54 is a diagrammatic representation of the systematic 
enzyme digestion ofNeu5Aca(2,3)Galp(l,6)Galp-0-CH2CH2SiMe3
Figure 54 Diagram of systematic
Neu5Aca(2,3)GaIp(l,6)Galp-0-CH2CH2SiMe3(25)
enzyme digestion
AcHN
HO
Subject to C. perfringen. 
neuraminidase hydrolysis
Another possible 
point o f sialyiation
Subject to 
G p-Galactosidase 
hydrolysisO
SiMe.
Neu5 Aca(2,3)Galp( 1,6)GalpO-CH2CH2SiMei
80
This suggests the formation of the linear trisaccharide arising from the sialyiation of 
the non-reducing terminal galactose unit, rather than the alternative (literature 
supported) branched product.
4.6 Sialyiation of Glcp(l,6)Galp-Octyl (20)
Glcp(l,6)Galp-0ctyl has been proven to be a good substrate of ^ f^a«5-sialidase. This 
is possibly as a result of the orientation of the galactose moiety at the 6 position. 
This is a significant result, since only the sialyiation of terminal galactose residues 
has been reported in the literate.
4.6.2 Preparative scale sialyiation of G lcp(l,6)Galp-0-0ctyl (20)
In an attempt to prove the sialyiation of Glcp(l,6)Galp-0-Octyl, the incubation of 
this sugar was increased to a preparative level of approximately 3 mgs. Since the 
sialyiation of oligosaccharides by /rawj-sialidase is a reversible reaction and the 
products of the reaction are substrates for the back reaction, as well as the fact that 
the sialylated sugai*s are unstable, this was a difficult task. However a product 
(approximately 1.5 mg) was isolated which had the assumed correct Rf valve by 
T.L.C. The proposed sialyiation of Glcp(l,6)Galp-0-0ctyl by /row^-sialidase is 
shown below in Figure 55.
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Figure 55 Sialyiation of Glcp(l,6)Galp-Octyl (20)
AcHN OPNP
Neu5Ac-0-PNP
fraw '^-sialidase
OH^O
O-Octyl 
OH
Glcp(l,6)Galp-0-0ctyl (20)
0  HO 
GO2 OH 'O
AcHN O-Octyl
Neu5Ac[Glcp(l ,6)]Galp-0-0ctyl (26) 
M ol Wt.: 744.76
4.6.3 Analysis of Neu5Aca(2,3)[Glcp(l,6)]Galp-0-Octyl (26) 
Mass Spectrometry
Electrospray
The compound was subject to Electrospray Mass Spectrometry. The spectrum was 
run from 500-900 Da/e. The calculated molecular weight for this compound is 
744.76. The spectrum shows clearly only one peak at 745 Da/e. This corresponds to 
Neu5Aca(2,3)[Glcp(l,6)]Galp-0-0ctyl. Shown below in Figure 56 is the mass 
spectrum.
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Figure 56 Mass spectrum of Neu5Aca(2,3)(Glcp(l,6)]Galp-0-0ctyl (26)
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4.6.4 Systematic enzymatic digestion Neu5Aca(2,3)[GIcp(l,6))Galp“0-0ctyI 
(26)
Neu5Aca(2,3)[Glcp(l,6)]Galp-0-0ctyl was isolated and then subjected to systematic 
enzymatic digestion using p-glucosidase {Caldocellum saccharolyticum), p- 
glucosidase [almond extract (both crude and 98 % pure)], p-galactosidase {E. coli) 
and neuraminidase (C. perfringens). Figure 57 shows a photograph of the T.L.C. 
plate of the enzymatic digestion ofNeu5Aca(2,3)[Glcp(l,6)]Galp-0-Octyl.
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Figure 57 Systematic enzymatic digestion Neu5Aca(2,3)[GIcp(l,6))GaIp-0- 
Octyl (26)
5.5 cm
" a #
0 cm
# •
# # * * 1 • ,  T
•  •  •  •  * •  l  à *  *
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Legend of Figure 57
Lane 1 N euSA c Marker, R f =  0 Lane 9 Incubation e, N eu 5A ea(2 ,3 )[G leP (I ,6 )]G a ip -  
O -Octyl w ith C. perfringens  neuraminidase, and P- 
glucosidase, R f =  0 .4  (sm eared)
Lane 2 G lucose Marker, R f =  0 .4 Lane 10 Incubation f. N eu 5 A ca (2 ,3 )[G lcp (I.6 )]G a ip -  
O -Octyl. R f  =  0.4
Lane 3 Oetyl lactoside Marker, R f  =  0.7 Lane 11 Incubation g. Octyl lactoside with p- 
galaetosidase. R f  =  0 .4
Lane 4  G alactose Marker, R f — 0.4 I ^ e  12 Incubation h. Octyl lactoside with P- 
glucosidase, R f  =  0.6
Lane 5 Incubation a, N eu 5A ca(2 .3 )[G lcP (I ,6 )]G a ip -  
O -Oetyl w ith p -glucosidase, R f  =  0.4
Lane 13 Incubation j , G lc P (l,6 )G a lp -0 -0 c ty l w ith C. 
perfringens  neuraminidase and P -galactosidase (grade 
VIII), R f  =  0.6
I ^ e  6 Incubation b. G lcP (I ,6 )G a ip -0 -0 e ty l w ith P- 
glueosidase, R f  =  0.3
Lane 14 Incubation k,
N e u 5 A ca (2 ,3 )[G lcP (I ,6 )]G a ip -0 -0 c ty l with C. 
perfringens  neuraminidase and P-galactosidase R f =  
0 .6
Lane 7 Incubation c, N eu 5A ca (2 ,3 )[G lcP (I ,6 )]G a lp -  
O-Octyl w ith C. perfringens  neuraminidase, R f  =  0 .6
Lane 15 N eu 5 A ca  (2 ,3 )[G lc P (l,6 )]G a ip -0 -0 e ty l  
Marker, R f =  0 .5 , 0.4
I,ane 8 Incubation d, G lcP (I ,6 )G a lp -0 -0 c ty l w ith C. 
perfringens  neuraminidase, R f  =  0 .6
L.ane 16 G lc P (l,6 )G a lp -0 -0 c ty l Marker, R f = 0 .7
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4.6.5 Treatment of Neu5Aca(2,3)lGlcp(l,6)]GaIp-0-0ctyl (26) with C. 
perfringens neuraminidase and p-glucosidase
Neu5Aca(2,3)[Glcp(l,6)]Galp-0-0ctyl is not subject to hydrolysis by p-glucosidase 
(crude, almonds). This does not indicative that Neu5Ac is attached to glucose, (since 
there is no literature precedent for this). It is more likely that the branched 
trisaccharide (26), is too large for the p-glucosidase binding site, and hence is not 
digested. An attempt to degrade (26) by alternative p-glucosidases was also 
examined, (see page 86) but was also unsuccessful.
C. perfringens neuraminidase will remove sialic acid to give Glcp(l,6)Galp- 
O-Octyl. Further degradation of Glcp(l,6)Galp-0-0ctyl by p-glucosidase followed 
by p-galactosidase produces glucose and galactose. Neuraminidase has no affect on 
the Glcp(l,6)Galp-0-0ctyl (expected).
Treatment of Glcp(l,6)Galp-0-0ctyl with p-galactosidase leaves
Glcp(l,6)Galp-0-Octyl unchanged, as expected. A diagrammatic illustration of 
possible sites and sequence of enzymatic digestion is shown below in Figure 58.
Figure 58 Digestion of Neu5Aca(2,3)IGIcp(l,6)]Galp-0-0ctyI (26) by C. 
perfringens neuraminidase and p-glucosidase
2. Subject to p-glucosidase 
hydrolysis? (Only after 1.)OH
HO
OH
HO
HO OH
O-Octyl
HO OH
Neu5Aca(2,3)[Glcp( 1,6)]Galp-0-0ctyl (26)
1. Subject to C. perfringens 
neuraminidase hydrolysis
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4.6.6 Digestion of Neu5Aca(2,3)[Glcp(l,6)]Galp-0-0ctyl (26) by other p- 
glucosidases
Neu5Aca(2,3)[Glcp(l,6)]Galp-0-0ctyl was tested for susceptibility by another p- 
glucosidase to establish whether or not it was only resistant to only p-glucosidase 
(crude, almonds) and to hopefully establish the point of attachment of sialic acid. .
(26) was assayed with p-glucosidase {Caldocellum saccharolyticum). This study 
indicated that p-glucosidase {Caldocellum saccharolyticum) is not able to digest (26) 
[similar* to p-glucosidase (ahnonds)] and gave no information as to the point of 
attachment ofNeu5Ac.
4.7 Sialyiation of Galp(l,4)[pGal(l,6)lGlcp-0-0ctyl (21)
The sialyiation of Galp(l,4)[pGal(l,6)]GlcNAcp-0-0ctyl has previously been 
illustrated, see Figure 50, page 75. Galp(l,4)[pGal(l,6)]Glcp-0-0ctyl was 
synthesised chemically {Kartha and Field 1997), to reflect one of the naturally 
occurring trisaccharide fragments of Trypanosoma cruzi, [All of the naturally 
occurring oligosaccharide fragments (both human and insect form) are shown in 
Figures 42 and 43, pages 64 and 66]. Hence the sialyiation and characterisation of 
Neu5Aca(2,3)Galp(l,4)[pGal(l,6)]Glcp-0-0ctyl is important in the mapping of the 
enzyme binding site.
4.7.2 Preparative scale sialyiation of Galp(l,4)[pGal(l,6)]Glcp-0-0ctyl (21)
In an attempt to prove this sialyiation, the incubation of Galp(l,4)[pGal(l,6)]Glcp-0- 
Octyl was increased to a preparative level of approximately 3 mgs. As before, the 
sialyiation of this sugar by /ra«5-sialidase is reversible with the sialylated product 
being a substrate for the back reaction, hence isolation is difficult. A product 
(approximately 1 mg) was isolated. By T.L.C. the second sialylated product was 
recognisable. A photograph was taken to record the second product visible by T.L.C. 
This is shown below in Figure 59.
86
Figure 59 Di-sialylation of Galp(l,4)[pGaI(l,6)]GlcNAcp-0-0ctyl (21)
Legend of Figure 59
Lane 1 Sialyiation o f  G a lp (l,4 )[p G a l( l,6 )]G lc p -0 -  
Octyl R f  =  0.4, 0 .2
Lane 2 G a lp (l,4 )[P G a l(l,6 )]G lc p -0 -0 c ty l R f  =  0.5
Shown below in Figure 60 is the proposed enzymatic sialyiation of 
Galp(l ,4)[pGal(l ,6)]Glcp-0-0ctyl.
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Figure 60 Sialyiation of Galp(l,4)[pGal(l,6)]Glcp-0-0ctyl (21)
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O-OctylHQHOOPNP
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Galp(l,6) (21)
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\  Neua(2,3)Galp(l,4)plcp-0-0ctyl 
Neua(2,3)Galp(l,6) (28)
(Minor product, 1197.16 Da/e)
HO
HO V\cHN OH
4.7.3 Analysis of sialylated-(2,3)Galp(l,4)[pGal(l,6)]Glcp-0-0ctyl (27) and 
(28) - Electrospray Mass Spectrometry
The compound was subject to Electro spray Mass Spectrometry. The spectrum is 
shown below in Figure 61. The spectrum was run from 700-1300 Da/e. (However 
it should have been from 550 to observe the di-charged species at 598.57 Da/e. 
There are clearly two peaks as expected by T.L.C., these are located at 906.99 and
1197.16 Da/e, corresponding to the mono (27) and di-sialylated (28) 
Galp(l,4)[pGal(l,6)]Glcp-0-0ctyl. By MS there are two products, one located at
1197.16 and the other at 906.99, approximately 290.27 Da/e apart. The molecular 
weight of Neu5Ac is 308.26 (subtracting OH = 17.01) leaves 291.25. (The peak 
height at 1197.16 is smaller than expected, since this is the singularly charged 
species. It is suspected that there will be a much larger peak at 598.57).
Figure 61 Mass Spectrum of sialylated-Galp(l,4)[pGal(l,6)]Glcp-0-0ctyl 
(27) and (28)
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4.8 Conclusions
Based on the natural Trypanosoma cruzi cell surface sialic acid acceptors, a variety 
of oligosaccharides, compounds (14)-(21) were chemically synthesised {Kartha
1997). These compounds were subject to a radiochemical assay, to assess their 
potential as substrates {Pereira et al 1995, Vetere et al 1996). Compounds (14) and 
(16)-(21) were found to be sialylatable substrates. This indicates that /raw^-sialidase 
has very little linkage specificity or size specificity. These findings concur with the 
results recorded by T.L.C.
The sialyiation of compounds (19), (20) and (21) indicate that it is possible to 
modify the hydroxyl group at position 6 of galactose-X acceptors i.e. ^ra«5'-sialidase 
will permit even another monosaccharide at position 6 without any negative effects 
on sialyiation. This result agrees with the sialyiation of compounds 3(i,ii,iii,iv) and 
8(i,ii,iii,iv) from previous studies. The lack of specificity of ?ra«^r-sialidase towards 
the hydroxyl group at position six of the terminal (or otherwise) p-galactose could 
tolerate significant modification. As described before, this could encompass a solid- 
phase linker to exploit this enzyme in oligosaccharide chemistry {Whittaker et al 
1996).
The sialyiation of p-aminobenzyl-l-thio-p-S-galacto-pyranoside resin {Sigma 
Chemicals Ltd) (confirmed radiochemically) indicates that it is possible to sialylate 
more than one neighbouring galactose moiety. This result is compounded with the 
formation of compound (28) which was proved by T.L.C. and radiochemically 
before characterisation by electrospray-mass spectrometry.
Sialyiation of an internal non-reducing galactose (20) has been carried out 
successfully. The product (26) was confirmed radiochemically and by T.L.C. before 
being isolated and characterised by electrospray-mass spectrometry and enzymatic 
digestion. This result is novel and could be exploited in synthetic oligosaccharide 
chemistry, to possibly sialylate other internal (3-gal residues.
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Chapter 5
trara-Sialidase substrate 
recognition of modified 
Galp-S-X analogues
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5.1 Substituted Galp-S-X analogues
Characterisation of the enzyme binding site and its recognition of terminal galactose, 
was carried out using a library of modified sugars. A library of modified thiol 
galactose sugars was obtained from Ole Hindsgaul’s laboratory, Alberta, Canada. 
These compounds had been synthesised for the purpose of a study of cholera toxin 
1998, This basic sugar skeleton reacted twice with a variety of substituents as 
outlined in Figure 62.
Figure 62 General scheme for the formation of the library of Galp-S-X 
oligosaccharides
Of^OR ^  bR U
\— Q ,0R = Protecting group
-O + Or 
R O ^ W ^ S H  ^ O^O R
OR
RO
OR
RO
OR
The first reaction (Michael addition) was carried out using substrates 1-10. The 
second reaction (Imine formation) then followed using substrates A-J. Galp-SH and 
all of the compounds which it was reacted with are shown below in Figure 63.
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5.2 Galp-S-X radiochemical assay
Each of the 100 Galp-S-X analogues (compounds Al-JlO) was assayed 
radiochemically {Pereira et al 1995, Vetere et al 1996). The graphs below in Figure 
64 represent all of the Galp-S-X oligosaccharides incubated. The results may be 
interpreted as before, i.e. a value of 0-15 % elution/total represents a good substrate, 
whereas >35 % represents a non-substrate. In this screen the columns above with 
E/Total % = 0 represents a substrate which was unavailable. The results are based 
on a radioactive assay which was carried out twice.
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Figure 64 The complete substituted Galp-S-X oligosaccharide library
sub  cnz
3
Al-lO G alp-SXanalogues Bl-10 G alp-SX analogues
sub  cn/.
Cl-lO  G alp-SX  analogues
sub  enz
Dl-lO  G alp-SX  analogues
1 2 3 4 5 6 7 8 9 10 No No
El-10 G alp-SX analogues F l- lO  G a l p - S X  a n a l o g u e s
I 2 3 4 5 6 7 8  9 I 0 N o N o 1 2 3 4 5 6 7 8 9 10 No No
Gl-10 Galm-SX analogues H I - 10 G a l p - S X  a n a lo g u e s
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11-10 Galp-SX analogues Jl-10 Galp-SX analogues
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It is apparent that from these plots that some of these compounds are particularly 
good substrates for rra«5-sialidase. However there seems to be no particular pattern 
to the substrate specificity. The above data can confirm that trans-siaWdase is an 
excellent sialyl transferase, having the capability to exploit many diverse 
oligosaccharides. The best substrates of this library were incubated again 
radiochemically {Pereira et al 1995, Vetere et al 1996) with the best substrates from 
all of the other screens and the results plotted as before. The results are shown 
below in Figure 65.
Figure 65 Graph of the best /ra/is-sialidase substrates
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J6 was selected as the best substrate of this library and was subject to a serial 
dilution. The structure of this compound is illustrated below, in Figure 66.
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Figure 66 The best substrate of the substituted Galp-S-X oligosaccharide 
library, J6
OH^OH
OH
HoN
NH
NH
HN COOH
S
Only one of the four possible stereoisomers is shown above.
5.3 Serial dilution of J6 and Galp(l,4)[pGal(l,6)]Glcp-0-0ctyl (21)
A serial dilution was carried out fi’om 1 ml to 50 pi in order to calculate IC50 values 
for substrates of /ra«5-sialidase. J6 and Galp(l,4)[pGal(l,6)]Glcp-0-0ctyl were 
selected as the substrates which gave the best % turnover. Figure 67 shows the 
graph of substrate J6 in comparison to Galp(l,4)[pGal(l,6)]Glcp-0-0ctyl.
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Figure 67 Graph of J6 and GaIp(l,4)[pGaI(l,6)]Glcp-0-0ctyI % turnover 
comparison
e  25 Q
-3 20
Concentration niM
The blue line is Galp(l,4)p[Gal(l,6)]Glcp-O-Octyl and Red line is J6.
From this graphical illustration, IC50 values are estimated based no enzyme/substrate 
present giving a value of 5 % (Elution/Total, DPM) and no substrate present giving a 
turnover of 35 % and 33 % for J6 and Galp(l,4)p[Gal(l,6)]Glcp-0-0ctyl 
(Elution/Total) respectively, (Therefore 5 % = 0 and 35 % or 33 % = 100).
J6 IC50 = 1.62 mM and Galp(l,4)p[Gal(l,6)]Glcp-O-OctylIC50= 1.55 mM 
As these substrates both have a considerable size requirement, it is obvious that 
either the side chains are oriented such that they are in space, or the enzyme binding 
site is larger enough to accommodate this size.
5.4 Conclusions
This study of structurally diverse Galp-S-X analogues was comprehensive in its 
assessment of tmns-sïdXïéàSQ as a potential oligosaccharide. Of the 100+ galactose- 
based diastereoisomer acceptor substrates analysed (compounds Al-JlO), greater 
than 75 % served as /ra«5-sialidase substrates. The results of this and previous 
studies indicate that /ran^'-sialidase is a versatile reagent for sialyl-glycoconjugate 
synthesis.
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The best acceptor substrate of the 100 Galp-SX analogues was found to be 
compound J6 . J6  contains a large aliphatic side chain containhig one carboxylic 
acid group and a guanidino group at its tail. From this study it is not possible to 
confirm whether the charged tail is significant for improved trans-siaXïàdiSQ substrate 
specificity. However, it is probably more likely that trans-smlidasQ more generally, 
has a lai'ge size requirement, as suggested from previous findings (19), (2 0 ), (2 1 ) and 
also J6 . A serial dilution was carried out using both J6  and (21) to allow IC50 values 
to be measured. The values for 50 % inhibitor are as follows, J6  IC50 = 1.62 inM 
and(2 1 )IC 5o= 1.55 mM.
99
Chapter 6
Experimental
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A .l List of Suppliers
Amershaiti Life Sciences
• [^"^C]Lactose 
Am icon
50 kDa Centricon filters 
Coomassie brilliant blue 
BioRad
SDS-Polyacrylamide “Ready” gels 
Reverse-phase Silica 
isher Scientific (bulk reagents and supplies)
NazCOg 
NH4OAC 
(NH4>2S04
MeOH, CHCI3 
Imidazole 
AgNOs 
CH3COOH 
H3PO4 
Na2S2 0 3
Thin Layer Chromatography Plate (Whatman, K6F Silica Gel 60A, 20 cm 20 cm, 
thickness 250 t^m)
Merek
• Optiphase Scintillation Cocktail 
Qiagen
• Nf"*" NTA chelation affinity resin 
Sigma
• A25 Sephadex anion exchange resin
• p-galactosidase (E. coli) B.C. 3.2.1.23 (G5635)
• p-glucosidase (Almonds, Crude) B.C. 3.2.1.21 (G 0395)
• p-glucosidase (Almonds, purified) B.C. 3.2.1.21 (G 4511)
• p-glucosidase {Caldocellum saccharolyticum) B.C. 3.2.1.21 (G 6906)
• Neuraminidase (C. perfringens) B.C. 3.2.1.18 (N 2876)
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Sigma (Cont.)
• Trizma (HCl, 99 % pure)
HEPES (Na sait, 99.5 % pure)
MES (Monohydrate, >99.5 % pure) 
p-Aminobenzyl-1 -thio-p-S-galacto-pyranosidase 
D-Lactose (Monohydrate)
D-Galactose (99 %)
D-Glucose (anhydrous, 99.5 %)
LB Broth, Miller 
LB Agar, Miller 
Ampicillin
Kanamycin Monosulfate 
Sodium Phosphate 
Lysozyme 
EDTA 
DNase 1
p-mercaptoethanol 
Bovine Serum Albumin 
Toronto Research Chemicals
• 2,3-dehydro-2-deoxy-Neu5Ac 
Waters
Sep-Pac reverse-phase resin cartridges
10%
Source of recombinant ^m«s-sialidase
E. coli culture expressing recombinant /raw^-sialidase protein was sent from Sergio 
Schenkman’s Laboratory at the Department of Cell Biology, Escola Paulista de 
Medicina, Sao Paulo, Brazil. This 70 kDa construct contains the catalytic head 
region and incorporates a hexa-histidine tag at the C-terminus. This protein was 
isolated using standard molecular biological techniques and then purified. The hexa- 
histidine tag aided the separation of the enzyme by nickel affinity chromatography. 
This enzyme has been purified to a single band by SDS-PAGE (silver stain), see 
Appendix 1 for full purification details, Schenkman et al 1997). It was found, 
however that the purified material was less stable tlian crude material. It was found 
that crude lysate had sufficient enzymatic activity and increased stability. Hence 
crude material was used for all of the subsequent studies.
^ra/is-Sialidase donor and acceptor substrates
Unless otherwise stated the carbohydrate donor and acceptor substrates for all of the 
biological assays, as well as the Galp(l,X)Gal acceptor substrates were synthetically 
made “in house” by K. P. R. Kartha.
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6.1 Assay development
All of the following assays were carried out using a variety of substrates and with 
either ^raw '^-sialidase and C. perfnngens neuraminidase (or both).
The experimental procedure was the same for all experiments, and is as 
follows: all of the components were incubated together at 37 for the time 
indicated. The reaction was quenched with 1 ml of Na2C0 3  (100 mM) pH 10, before 
the absorption was measured. In some cases the assay was carried out in duplicate or
triplicate. In these cases an average best represented the absorption results.}
6.1.2 Spectrophotometric assay of ^raw -^sialidase and C. perfringens 
neuraminidase
^ra«5-Sialidase and C. perfringens neuraminidase were assayed using Neu5Ac-0- 
PNP as a substrate and lactose as an acceptor. The incubation included 0.1 units of 
C. perfringens neuraminidase or an undetermined amount of rra«5-sialidase. 
Although no formal calculation was made on the activity of /rc/w^-sialidase, the level 
of activity was comparable with the other neuraminidase in all cases. All of the 
assay components, including concentrations, are listed below in Table 4.
Table 4 trans-smlidase and C. perfringens neuraminidase assay 
components
Component Stock Cone. Volume 50 pi
Neu5Ac-0-PNP 5 mM 10
Lactose (or H2O) 5 mM 10
HEPES buffer 150 mM 10
H2O - 10
C. perfringens neuraminidase or 
^ra«5-sialidase
See above 10
The results of the assay were tabulated and are shown below in Table 5 -
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Table 5 Comparison of ^mns’-sialidase and C. perfringens neuraminidase
reaction rates
Incubation AA400 (After 30 Mins)
Control 0.05
/raw^-sialidase (-) lactose 0.06
/raw^-sialidase (+) lactose 0.14
C. perfringens neuraminidase (-) lactose 0.58
C. perfringens neuraminidase (+) lactose 0.62
This study indicates that C. perfringens neuraminidase is a hydrolase, and that the 
presence of an acceptor such as lactose makes no significant difference. However 
there is a significant difference when an acceptor such as lactose is added to the 
/rfliii'-sialidase incubation. This confirms that ^mw-sialidase is preferentially a 
transferase.
6.1.3 Comparison of 2‘rafi5-sialidase transferase and hydrolase activities
Since Neu5 Ac-O-PNP was not a particularly good donor substrate for our purposes a 
coupled assay was developed, replacing Neu5Ac-O-PNP with Neu5 Aca(2,3)Galp-0- 
PNP. This would require the introduction of a p-galactosidase.
6.1.3.2 First coupled assay for tra/is-sialidase using lactose as an acceptor
Since ^ra«5-sialidase is both a transferase and a hydrolase a new coupled assay 
incorporating both these reactions was developed. This coupled assay uses 
Neu5Aca(2,3)-Galp-0-PNP as a donor substrate and lactose as an acceptor sugar, p- 
Glucosidase which also possessed some p-galactosidase activity, was used to 
hydrolyse the resulting Galp-O-PNP bond. This assay was buffered at pH 6.5. The 
assay components are outlined below in Table 6.
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Table 6 Comparison of /mifs-sialidase transferase and hydrolase assay
(mark I) components
Component Stock Cone. Volume 50 pi
Neu5Ac-O-PNP or Neu5Aca(2,3)-Galp-0-PNP 5 mM 10
Lactose (or H2O) 5 mM 10
HEPES buffer 150 mM 10
H2O - 10
/ra«5-sialidase or C. perfringens neuraminidase See above 10
These components were assayed as before and the results are shown below in Table 
7.
Table 7 Comparison of ^ rans-sialidase transferase and hydrolase activities 
(mark I)
Incubation AA400 (After 30 Mins)
rr««5-sialidase (-) lactose (Neu5Ac-PNP) 0.06
trans-siaXiédi^Q (+) lactose (Neu5Ac-PNP) 0.14
trans-sialidasQ (-) lactose (Neu5Ac-Gal-PNP) 0.23
transsialidasQ (+) lactose (Neu5Ac-Gal-PNP) 0.47
6.1.4 Comparison of C. perfringens neuraminidase activity with and without 
acceptor
A similar assay was carried out using the same components as before but with C. 
perfringens neuraminidase assay was carried out utilising both Neu5 Ac-O-PNP and 
Neu5Aca(2,3)Galp-0-PNP. The results of the C. perfringens neuraminidase assay 
were tabulated and are shown below in Table 8.
Table 8 Comparison of C. perfringens neuraminidase with and without 
acceptor
Incubation AA400 ( 30 Mins)
Control (C. perfringens neuraminidase) 0
C. perfringens neuraminidase (-) lactose (Neu5 Ac-PNP) 0.58
C. perfringens neuraminidase (+) lactose (Neu5Ac-PNP) 0.62
C. perfringens neuraminidase (-) lactose (Neu5Ac-Gal-PNP) 0.46
C. perfringens neuraminidase (+) lactose (Neu5Ac-Gal-PNP) 0.47
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6.1.5 Coupled assay for ^mifs-sialidase using Galp(l,3)GlcNAcp-0-0ctyl as an
acceptor (mark II)
As outlined on page 34, it was found that the acidic pH of the /raws'-sialidase coupled 
spectrophotometric assay was creating a problem. The coupled assay was adapted to 
overcome this problem. The pH was increased which resulted in a new p- 
galactosidase being used and hence another acceptor was selected which was 
unsusceptible to p-galactosidase activity. It was found that Galp(l,3)GlcNAcp-0- 
Octyl was a reliable acceptor substrate which was not subject to enzymatic 
degradation. Consequently a study was carried out on ^mw-sialidase using variable 
concentrations of donor substrate, in the presence and absence of an acceptor to 
optimise assay conditions. A control was also carried out to monitor the background 
hydrolysis rate. The assay components are shown below in Table 9.
Table 9 Coupled assay for /mns-sialidase assay components (mark II)
Component Stock Cone. Volume 50 pi
Neua(2,3)Galp-0-PNP 5 mM 10
Galp(l ,3)GlcNAcp-0-Octyl 5 mM 10
p-galactosidase {E. coli) 80 units 10
HEPES buffer 150 mM 10
/ra«5-sialidase and C. perfringens 
neuraminidase
As before 10
The components were assayed as before and the results of the incubation are shown 
below in Table 10.
Table 10 Results of coupled assay for /m/i5-sialidase (mark II)
Incubation AA400 (After 30 Mins)
Control (^ra«.ÿ-sialidase) 0.01
rra«.s-sialidase (-) acceptor 0.19
/raw^'-sialidase (+) lactose 0.38
/ra«.s-sialidase (+) Galp(l,3)GlcNAcp-0-0ctyl 0.47
This table shows that Galp(l,3)GlcNAcp-0-0ctyl is a significantly better acceptor 
than lactose.
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6.1.6 Spectrophotometric coupled assay (mark II) using a variable 
concentration of donor substrate (Neua(2,3)Galp-0-PNP)
These incubations were repeated several times with various concentrations of 
substrate and a representative average was calculated of each. The results are as 
follows in Table 11.
Table 11 /ra/ts-sialidase assay (mark II): variable concentrations of donor 
substrate with and without acceptor (After 30 Mins)
Substrate concentration AA400
(+ ) 5 mM Galp 
(l,3)GlcNAcp-0-0ctyl
AA400
(-) 5 mM Galp 
(l,3)GlcNAcp-0-0ctyl
1 mM 0.08 0.06
2 mM 0.25 0.08
3 mM 0.27 0.09
4 mM 0.41 0.08
5 mM 0.51 0.14
6.1.6.2 Am and Fmax for /rawf-sialidase
The Am and Fmax values were estimated for /raw^-sialidase based on enzyme 
incubations. fmw-Sialidase was incubated 37 ”C, for 30 minutes, with 5 mM - 25 
mM stock concentrations of Neu5Ac-a-2,3-Gal-p-0-PNP (Donor substrate) and with 
and without 5 mM (stock) Gal-p-1,3-GlcNAc-O-Octyl.
Using these figures, Tables 12 and 13 and using the Beer-Lambert Law (A = scl) 
we can construct a Lineweaver-Bm*k double reciprocal plot. The molar extinction 
co-efficient for p-nitrophenol = 18 300 MT^  cm”’ (absorption 400 nm) (Byers et al 
1985). For example, /^ ’ows'-sialidase (transferase), 1 mM concentration gives a value 
of V as follows:
108
Since A = scl, 0.078 = 18 300cl, 
c = 4.26 \iM in 1 ml 
i.e. 4.26 nmoles of PNP produced in 30 minutes (incubation time)
.-.0.142 nmol/min
Table 12 1/[S] and 1/v values for tmitv-sialidase, the transferase
Substrate 
Concentration, [S]
1/[S] mM ^ AA400
(-) Acceptor*
V
nM min ’
1/v
min nM^
1 mM 1 0.08 0.14 7.04
2 mM 0.5 0.25 0.46 2.17
3 mM 0.33 0.27 0.49 2.04
4 mM 0.25 0.41 0.74 1.34
5 mM 0.2 0.51 0.92 1.08
* Each substrate concentration w as repeated three tim es. The eiTors in  the assay are approxim ately + / - 1 0  %.
Table 13 1/[S] and 1/v values for tm/fv-sialidase, the hydrolase
Substrate 
Concentration, [S]
1/[S] mM ’ AA400
(-) Acceptor*
V
nM min ’
1/v
min nM ’
1 mM 1 0.06 0.11 9.35
2 mM 0.5 0.08 0.15 6.80
3 mM 0.33 0.09 0.17 5.78
4 mM 0.25 0.08 0.15 6.71
5 mM 0.2 0.14 0.26 3.85
* Each substrate concentration w as repeated three tim es. The errors in the assay are approxim ately + / - 1 0  %.
6.1.7 Incubation of /raw^-sialidase and C. perfringens neuraminidase with 2,3- 
dehydro-2-deoxy-Neu5Ac
/ra«5-Sialidase and C. perfringens neuraminidase were incubated with 2,3-dehydro- 
2-deoxy-Neu5Ac. This acts as an inhibitor of C. perfringens neuraminidase, but not 
/rfl«5-sialidase. Again this was incubated in our assay system (same conditions as 
before) with C. perfringens neuraminidase and trans-sialidase and the relative 
turnover rate calculated. Shown below in Table 14 is a comparison of relative 
enzymatic activity of C. perfringens neuraminidase and trans-siaXidasQ with 
disaccharide substrate and 2,3-dehydro-2-deoxy-Neu5Ac present.
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Table 14 Assay components of spectrophotometric inhibitor study on trans- 
sialidase and C perfringens neuraminidase
Component Stock Cone. Volume 50 pi
2,3 -dehydro-2-deoxy-Neu5 Ac 5 mM 10
H2O - 10
Galp(l ,3)GlcNAcp-0-0ctyl 5 mM 10
HEPES buffer 150 mM 10
/rartj'-sialidase and C. perfringens neuraminidase As before 10
The assay results are shown below in Table 15
Table 15 Results of the spectrophotometric inhibitor study on trans- 
sialidase and C perfringens neuraminidase
Incubation AA400 (After 30 Mins)
^raMj-sialidase 0.33
^ra«5'-sialidase + Inhibitor 0.35
C. perfringens neuraminidase 0.37
C. perfringens neuraminidase + Inhibitor 0.02
These results indicate that 2,3-dehydro-2-deoxy-Neu5Ac is an inhibitor of C. 
perfringens neuiaminidase but not of /raw^-sialidase. This indicates that trans- 
sialidase could possibly proceed through a different intermediate.
110
6.2 Sialylation of Galp-O-Octyl analogues
The diagram below. Figure 30 (shown before on page 46) shows the three positions 
which have been synthetically modified.
Figure 30 Synthetically substituted Galp-O-Octyl library {Lowary et al 1993)
OH
OHOH
HOHO Octyl o<
OH 
2 (UMIi.iv)
OH 
3 (iJUii.iv)
Octyl
X(i)  = H X (ii) = OMe
X (iii) = F X (iv) = NHg
6.2.2 Radiochemical assay of Galp-O-Octyl analogues {Lowary et al 1993)
All of the above substrates were assayed radiochemically {Pereira et al 1995, Vetere 
et al 1996) (page 48). The experimental procedure is outlined below.
6.2.3 Synthetically substituted Galp-O-Octyl radiochemical incubations
The radiochemical assay employed monitors the incorporation of lactose and 
results in the formation of anionic radio labelled Neu5Ac*GalGlc. This 
incorporation process shown below in Figure 21 (see before, page 32).
Figure 21 Incorporation of [*'*CJ lactose
©NeuSAcGalGlc + *GalGlc
©Neu5Ac*GalGlc + GalGlc 
^Radiochemical isotope incorporation
In this assay (with no alternative substrate present), /ra«5-sialidase will reversibly 
transfer sialic acid from sialyl lactose to [^ '^ C] lactose. The charged material can be 
separated from uncharged material by anion exchange chromatography as follows:
111
The assay mixture is loaded onto A25 resin {Sigma Chemical Ltd) and washed with 
water to remove all non-sialylated material (wash). The resin is then eluted with 
NH4OAC (eluent).
Since trans-sialiàasQ is a reversible sialyl transferase (provided the 
substrate/acceptor concentrations are equal and an equilibrium is established) the 
total number of radioactive counts in wash and the eluent should be approximately 
equal, thus:
/ra«5-sialidase 
and sialyl lactose
*lactose = *Wash  ^ r— *Eluent = *sialyl lactose
If a better trans-sialiàasQ substrate is added to the assay to compete with |
lactose, this will result in the unsialylated lactose being washed off the resin j
with H2O and hence the radioactive counts in the eluent will be significantly smaller. [
In some cases the alternative substrate is unsuitable for ^ram-sialidase to transfer j
sialic acid onto, hence the radioactive result will mirror that of no substrate present. ]
In this assay (with no alternative substrate), /raw^-sialidase will reversibly transfer I
sialic acid from sialyl lactose to lactose. Hence this results in the total number 1Iof radioactive counts in the wash and the eluent being approximately equal. If  a s
better /r«/7S'-sialidase substrate is added to compete with lactose, this will result |
in the unsialylated [^ '^ C] lactose being washed off and hence the radioactive counts in i
the eluent will be significantly smaller. In some cases the alternative substrate is i
unsuitable for /ra/î^-sialidase to transfer sialic acid onto, hence the radioactive result IIwill mirror that of no substrate present. The incubation was set up as follows:
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Table 16 Modified Galp-Octyl compound library radiochemical assay 
components
Volume Component
10 pi HEPES (250mM,pH7.0)
10 pi ["C] Galp(l,4)Glc (0.02 |j,Ci)
10 pi Neu5Aca(2,3)Galp(l,4)Glc (1 mM)
10 pi ^ra«5-sialidase
10 pi H2O or alternative substrate
These samples were incubated at 37 °C for 30 mins. 1 ml of H2O was then added 
before the incubation was loaded onto 0.5 mis of A25 Sephadex (Anion exchange 
resin), pre-swollen. The resin was then washed with 2 x 1 ml H2O before elution 
with 2 X 1 ml NH4OAC. All samples were collected and 8  mis of scintillation fluid 
(Optiphase) was added. The samples were then vortexed fully to ensure correct 
mixing before counting. (Each sample is counted for 5 nuns). The assay was 
repeated twice times.
Table 17 Substituted Galp-Octyl compound library radioactive Screen (All 
Numbers are in DPM)
Substrate Wash Elution Total E/Total %
l(i) 30325 19864 50190 40
2(i) 34558 15867 50425 31
3(i) 40645 9332 49977 19
1(H) 27805 22214 50019 44
2(H) 37547 14272 51818 28
3(H) 48006 3729 51735 7
l(iii) 40645 19439 60084 32
2(iii) 39311 12199 51511 24
3(iii) 44894 5981 50875 12
l(iv) 25587 26358 51945 51
2(iv) 35834 21895 57729 38
3(iv) 42372 14749 57121 26
No substrate 26269 26950 53210 51
No enzyme 55736 2756 52980 5
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Shown below in Figure 68 is a plot of the total counts of each compound 
1 (i,ii,iii,iv)-3(i,ii,iii,iv)
Figure 68 Graph of total radioactive counts (DPM) of each substituted 
Galp-O-Octyl analogues
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6.3 Galp-O-Octyl analogue incubations (using Neu5Ac-0-PNP as a 
substrate)
Compounds l(i,ii,iii,iv)-3(i,ii,iii,iv) {Lowary et al 1993), shown above (see before. 
Figure 30, page 46) were incubated with trans-sialidase as follows:
Table 18 Assay components of Galp-O-Octyl analogue incubations, 
monitored by T L C
Concentration Component
5 mg/ml (Approx.) rra/î^-sialidase (1 ml)
5 mM Neu5Ac-0PNP
1 mM Modified Galp-O-Octyl
250 mM HEPES (1 ml, pH 7.3)
The incubations were set up and left overnight, (~16 H) at 37 ‘^ C. 2 x 1  pi of each 
was loaded onto a T.L.C. plate and run in the solvent system CHCl3:Me0H:H20 
(120:85:20). The T.L.C. plate shows all of the modified 6 position octy 1-galactoses 
have been sialylated.
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6.3.2 Modified Galp(l,4)GlcNAcp-0-0ctyl library
The following 24 Galp(l,4)GlcNAcp-0-0ctyl substrates (also see Figure 36, page 
55), shown in Figure 36, were obtained from O Hindsgauf s Laboratory, Alberta, 
Canada.
Figure 36 24 Substituted Galp(l,4)GIcNAcp-0-0ctyl library {Hindsgaul el al
1996)
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6.3.3 Galp(l,4)GlcNAcp-0-0ctyl analogues radiochemical assay
The radiochemical assay was set up as before {Pereira et al 1995, Vetere et al 1996), 
see pages 48 and 111. Shown below in Table 19 is the total radioactive assay counts. 
The assay was repeated twice.
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Table 19 Amine substituted Galp(l,4)GlcNAcp-0-0ctyl analogues, 
radioactive screen (All Numbers are in DPM)
Compound Wash/DPM Elution/DPM Total/DPM % E/Total
9(i) 34005 13804 47809 29
10(i) 40679 7470 48149 16
5(i) 18062 31486 49548 64
6(0 17621 31954 49574 65
7(0 18215 27737 45952 60
8(0 36565 11850 48414 24
No substrate 28132 22835 51213 45
No enzyme 48388 5103 53491 9
Table 20 Acid substituted Galp(l,4)GlcNAcp-0-0ctyl analogues, 
radioactive screen (All Numbers are in DPM)
Compound Wash/DPM Elution/DPM Total/DPM % E/Total
9(ii) 73884 5506 79390 7
lO(ii) 44541 4826 49367 10
5(ii) 17740 30991 48731 64
6(ii) 19235 29435 48670 61
7(ii) 21172 28845 50017 58
8(ü) 42682 3981 46664 9
No substrate 28132 22835 51213 45
No enzyme 48388 5103 53491 9
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Table 21 Amide substituted Galp(I,4)GlcNAcp-0-0ctyl analogues, 
radioactive screen (All Numbers are in DPM)
Compound Wash/DPM Elution/DPM Total/DPM % E/Total
9(iii) 44899 6520 51419 13
lO(iii) 46389 4177 50566 8
5(ni) 29225 21573 50798 32
6(iii) 31635 19874 51509 39
7(iii) 32984 19163 52148 37
8(iii) 46586 4353 50940 9
No substrate 28132 22835 51213 45
No enzyme 48388 5103 53491 9
Table 22 Guanidino substituted Galp(l,4)GlcNAcp-0-0ctyl analogues, 
radioactive screen (All Numbers are in DPM)
Compound Wash/DPM Elution/DPM Total/DPM % E/Total
9(iv) 43960 8055 52015 15
lO(iv) 47382 3542 50924 7
5(iv) 28355 22592 50947 44
6(iv) 31357 18806 50163 46
7(iv) 28476 22785 51262 44
8(iv) 46109 5103 51212 10
No substrate 28132 22835 51213 45
No enzyme 48388 5103 53491 9
Shown below in Figure 69 is a plot of the total radioactive counts for each 
compound, 5(i,ii,iii,iv) -10(i,ii,iii,iv).
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Figure 69 Graph of total counts of Gaip(l,4)GlcNAcp-0-0ctyI analogues 
radiochemical assay
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Substituted Galp(l,4)GlcNAcp-0-0ctyl analogues
6.3.4 Substituted Galp(l,4)GlcNAcp-0-0ctyl incubation using Neu5Ac-PNP as 
a substrate (observed by T.L.C.)
Each of the 24 substrates were incubated with trans-sialidase as before, see pages 48 
and 111 and loaded onto a T.L.C. plate. They were run in the solvent system 
CHCbiMeOHiHiO (120:85:20). The T.L.C. plate showed that all of the six prime 
modified Gal(3(l,4)GlcNAcp-0-0ctyl have been sialylated.
6.4 Radiochemical assay of all Galp(l,X)Gal analogues (compounds (14)- 
(21))
The radiochemical assay was set up as before, see pages 48 and 111, using 
compounds (14)-(21), shown on page 67, {Pereira et al 1995, Vetere et al 1996).
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Table 23 is an average of the results shown in Table 24 and Table 25, which are 
also shown below.
Table 23
DPM)
Average % E/Total (DPM) of all Galp(l,X)Gal (All Numbers are in
Substrate %
E/Total
Substrate %
E/Total
A Galp(l,2)Galp-0-Me 15 H Galp(l,4)[Galp(l,6)Glc] p- 
O-Octyl
14
B Glcp(l,2)Galp-0-Me 26 I Galp(l,4)Glc 15
C Galp(l,3)Galp-0-Me 13 J Galactose 17
D Galp(l,3)GlcNAcp-0-0ctyl 12 K Glucose 26
E Galp(l,6)Galp-0-Me 8 L No inhibitor 27
F Galp(l,6)Galp-0- 
CHzCHzSiMes
6 M No enzyme 5
G Glcp(l,6)Galp-0-Octyl 10
Table 24 Total counts of Galp(l,X)Gal (compounds (14)-(21)) radioactive 
screen (All Numbers are in DPM)
Substrate Wash Elution Total E/Total %
Galactose 41034 8363 49397 17
Glucose 35981 12846 48829 26
Galp(l ,2)Galp-0Me 41276 7718 48994 16
Galp(l,3)Galp-OMe 43263 6717 49980 13
Galp(l ,6)Galp-OMe 45486 3478 48964 7
Galp(l,4)Glc 41013 7228 48241 15
No Inhibitor 35471 13112 48584 27
No Enzyme 46425 2300 48724 5
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Table 25 Total counts of GaIp(l,X)Gai (compounds (14)-(21)) radioactive 
screen (All Numbers are in DPM)
Substrate Wash Elution Total % E/Total
Galp(l,2)Galp-OMe 50152 7364 57516 13
Glcp(l,2)Galp-0Me 40602 14260 54861 26
Galp(l ,3)GlcN Acp-Octyl 49642 7080 56722 12
Galp(l ,6)Galp-0Me 49958 4450 54407 8
Galp(l,6)Galp-OCH2CH2Si(CH3)3 53035 3301 56336 6
Glcp(l ,6)Galp-Octyl 49152 5647 54799 10
Galp(l,4)[Galp(l,6)Glc]p-0-0ctyl 32121 7615 39736 14
No substrate 36029 19772 55801 35
No enzyme 54479 1923 56402 328
6.4.1.2 Sialylation of p-aminobenzyl-l-thio-p-S-galacto-pyranoside
(multi-pyranoside) resin
The results shown in Table 23 indicate the possibility of sialylation of an internal b- 
galactose moiety. Consequently, a radioactive assay was carried out using p- 
aminobenzyl-l-thio-p-S-galacto-pyranoside resin {Sigma Chemicals Ltd). This was 
to assess the possibility of multi-sialylation of oligosaccharides by /ra«5-sialidase. 
This resin was found to be a good substrate of trans-smiidase and consequently a 
serial dilution was carried out. The result of this study is shown below in Table 26.
Table 26 Serial dilution of/?-aminobenzyl-l-thio-p-S-galacto-pyranoside
p-aminobenzyl-l-thio-p-S- 
galacto-pyranoside Cone.
Wash Elution Total E/Total %
1 ml/200 gl 35879 5385 41264 13
lml/2 mis 27783 11541 39324 29
1 ml/20 mis 28593 16121 44714 36
No substrate 26020 16493 42513 39
No Enzyme 39145 2424 41569 6
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Using this data, we can construct Table 27 and calculate the % inhibition. A plot of 
log [I] versus % inhibition was then constructed.
Table 27 Relative inhibition of p-aminobenzyl-l-thio-p-S-galacto- 
pyranoside
Substrate
Cone.
gM E/Total % Minus
Background
%
Activity
%
Inhibition
1 ml/200 gl 86 13 7 21 79
lml/2 mis 8.6 29 23 70 30
1 ml/20 mis 0.86 36 30 91 9
No substrate - 39 33 - -
No Enzyme - 6 - - -
6.4.2 Incubation of Galp(l,X)Gal analogues (compounds (14)-(21)) with 
Neu5Ac-PNP (observed by T.L.C.)
Each of the Galp(l,X)Gal substrates (compounds (14)-(21)) were incubated with 
^ra«^-sialidase as before, see page 114 and loaded onto a TLC plate. The plates were 
run in the solvent system CHClsiMeOHiHaO (120:85:20). The results in each case 
were recorded and photographed.
6.4.3 Incubation of Galp(l,2)Gal-0-Me, Glcp(I,2)Galp-0-Me and 
Galp(l,3)Galp-0-Me
This T.L.C. plate shows that Galp(l,3)Galp-0-Me has become sialylated, producing 
a spot with an Rf = 0.3. Galp(l ,2)Galp-0-Me has also been sialylated, producing a 
spot with an Rf = 0.3. The T.L.C. also indicates that Glcp(l,2)Galp-0-Me has in no 
way been sialylated.
6.4.4 Incubation of Galp(l,6)Galp-0-CH2CH2Si(CH3)3, Glcp(l,6)Galp-0-0ctyl 
and Galp(l,6)Galp-0-Me
A similar experiment was carried out using Galp(l,6)Galp-0-CH2CH2Si(CHs)3, 
Glcp(l,6)Galp-0-Octyl and Galp(l,6)Galp-0-Me substrates. This T.L.C. shows that 
Galp(l,6)Galp-0-Me has become sialylated, producing a spot with an Rf = 0.3. 
Glcp(l ,6)Galp-0-0ctyl has also been sialylated, producing a spot with an Rf = 0.4.
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The T.L.C. also indicates that GaIp(l,6)Galp-0-Me has also been sialylated, 
producing a spot with an Rf = 0.1.
6.4.5 Incubation of Galp(l,4)[Galp(l,6)GIc]p-0-0ctyl and Glcp(I,6)GaIp-0- 
Octyl
This T.L.C. indicates that (with both 30 mM and 10 mM) Galp(l,4)[Galp(l,6)Glc]p- 
O-Octyl has become sialylated producing a spot with an Rf = 0.5 and Glcp(l,6 )Galp- 
O-Octyl has become sialylated, producing a spot with an Rf = 0.4.
6.4.6 3 mg Preparative Scale Synthesis of Neu5Aca(2,3)Galp(l,6)Galp-0- 
CH2CH2Si(CH3)3
3 mgs of Galp(l,6 )Galp-0 -CH2CH2Si(CH3)3 was incubated with 20 mgs of 
Neu5Ac-O-PNP. 4 mis of crude /raw^y-sialidase (approximately 5 mgs/ml) was 
added and the reaction mixture was buffered with 2 mis HEPES (250 mM, pH 7.3). 
The incubation was heated to 37 ®C and left for 16 hour s. By T.L.C. two spots (i.e. 
product and starting material) were present using CHCl3:Me0 H:H2 0  (120:85:20).
6.4.7 Purification of Neu5Aca(2,3)GaIp(l,6)Galp-0-CH2CH2Si(CH3)3
The product was then isolated on A25 sephadex anion exchange resin. The 
sialylated product was eluted with 1 M NH4OAC. The product was then separated 
further using Sep-Pac reverse-phase resin cartridges. The cartridges were first 
washed with H2O before the product being eluted in 100% MeOH. Approximately 
1.0 mgs of sialylated material was isolated. The product was then characterised by 
electrospray MS and enzymatic digestion.
6.4.8 Characterisation of Neu5Aca(2,3)Galp(l,6)Galp-0-CH2CH2Si(CH3)3 - 
Electrospray Mass Spectrometry
The spectrum shows clearly only one peak at 732.82 Da/e corresponding to 
Neu5Aca(2,3 )Galp( 1,6 )Galp -O-CH2CH2 Si(CHs)3. The calculated molecular weight 
for this compound is 732.78.
6.4.9 Enzymatic digestion of Neu5Aca(2,3)Galp(l,6)Galp-0-CH2CH2Si(CH3)3
Neu5Aca(2,3)Galp(l,6)Galp-0-CH2CH2Si(CH3)3 was subjected to systematic 
enzymatic digestion p-galactosidase {E. coli) and neuraminidase (C. perfringens).
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All incubations were carried out in MES (pH 5.5 50 gl), and heated to 37 over 
night. The incubation mixtures (a-f) were loaded onto a T.L.C. plate. They were run 
in the solvent system CHCI3iMeOHrHiO (120:85:20).
Incubation a indicates that Neu5 Aca(2 ,3 )Galp(l,6 )Galp-0 -CH2CH2Si(CH3)3 is not 
subject to hydrolysis by p-galactosidase as the trisaccharide has not changed on 
T.L.C. This is because the Neu5Ac is blocking the enzyme from cleaving the 
galactose residue and hence the trisaccharide cannot be digested.
Incubation b shows quite clearly the cleavage of the Galp(l,6)Galp0-0- 
CH2CH2Si(CH3)3 and the presence of galactose.
Incubation c shows the presence of starting material, Galp(l,6)Galp-0- 
CH2CH2Si(CH3)3 (as well as possibly Neu5Ac, very difficult to observe by T.L.C.), 
as expected from the removal of Neu5 Ac by C  perfringens neuraminidase.
Incubation d shows only Galp(l,6 )Galp-0 -CH2CH2Si(CH3)3 (as expected). 
Neuraminidase has no affect on the Galp(l,6 )Galp-0 -CH2CH2Si(CH3)3.
Incubation e shows galactose. As proven from incubation a and b, only after the 
sialic acid is cleaved by C. perfringens neuraminidase is it possible for the p- 
galactosidase to cleave Galp(l,6 )Galp-0 -CH2CH2Si(CH3)3. The smear at the base 
line is indicative of sialic acid.
Incubation f  shows the sialylated Glcp(l,6)Galp-0-0ctyl which is unchanged.
6.4.10 3 mg Preparative Scale Synthesis of Neu5Aca(2,3)[Glcp(l,6)]Galp-0- 
Octyl
Glcp(l,6)Galp-0-0ctyl was first purified to one spot by T.L.C. on reverse-phase 
silica. The product was eluted in a gradient of 100 % MeOH.
3 mgs of Glcp(l,6)Galp-0-Octyl was then incubated with 20 mgs of N#5Ac-O- 
PNP. 4 mis of crude ^roMJ-sialidase (approximately 5 mgs/ml) was added an^ (he 
reaction mixture was buffered with 2 mis HEPES (250 mM, pH 7.3). Itie incub^|^ç|p 
was heated to 37 °C and left for 16 hours. By T.L.C. two spots were present usjpg 
CHCl3:Me0 H:H2 0  (120:85:20).
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6.4.11 Purification of Neu5Aca(2,3)[Glcp(l,6)]Galp-0-0ctyl
The product was then isolated on reverse-phase silica. A gradient of 0-100% MeOH 
(In 25 % increments) was carried out. The product was isolated at 50 % MeOH. The 
product was then subject to further purification on A25 sephadex anion exchange 
resin. The sialylated product was eluted with 1 M NH4OAC. Approximately 1.5 mgs 
of sialylated material was isolated. This product was then characterised by 
electro spray MS and enzymatic digestion.
6.4.12 Analysis of Neu5Aca(2,3)[Glcp(l,6)]Galp-0-0ctyl - Electrospray Mass 
Spectrometry
The spectrum shows clearly only one peak at 745 Da/e. This corresponds to 
Neu5Aca(2,3)[Glcp(l,6)]Galp-0-0ctyl (calculated molecular weight 744.76).
6.1.14 Systematic enzymatic digestion Neu5Aca(2,3)[Glcp(l,6)]Galp-G-Gctyl
Neu5Aca(2,3)[Glcp(l,6)]Galp-0-0ctyl was subjected to systematic enzymatic 
digestion using p-glucosidase (Caldocellum saccharolyticum), (Almonds), p- 
galactosidase and C. perfringens neuraminidase. All incubations were carried out in 
(pH 5.5, 50 gl), and heated to 37 over night. The incubation mixtures (a-k) were 
loaded onto a T.L.C. plate. They were run in the solvent system CHCI3iMeOHiHiO 
(120:85:20).
Incubation a indicates that Neu5Aca(2,3)[Glcp(l,6)]Galp-0-0ctyl is not subject to 
hydrolysis by p-galactosidase as the trisaccharide has not changed on T.L.C. This 
may be for a number of reasons. It is not indicative that the Neu5Ac is attached to 
the galactose residue, (since there is no literature president for this). It is more likely 
that the branched trisaccharide is too bulky for the enzyme, and hence cannot be 
digested.
Incubation b shows quite clearly the cleavage of the Glcp(l,6)Galp-0-0ctyl and the 
presence of glucose. (Since glucose and galactose have very similar Rf values, it is 
very difficult to distinguish between the two).
Incubation c shows the presence of starting material, Glcp(l,6)Galp-0-Octyl (as well 
as possibly Neu5Ac, very difficult to observe by T.L.C.), as expected from the 
removal of Neu5 Ac by C. perfringens neuraminidase.
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Incubation d shows only Glcp(l,6)Galp-0-0ctyl (as expected). Neuraminidase has 
no affect on the Glcp(l,6)Galp-0-0ctyl.
Incubation e shows glucose (and galactose). As proven from incubation a and b, 
only after the sialic acid is cleaved by C. perfringens neuraminidase is it possible for 
the p-glucosidase to cleave Glcp(l,6)Galp-0-0ctyl. The smear at the base line is 
indicative of sialic acid.
Incubation f  shows the sialylated Glcp(l,6)Galp-0-0ctyl which is unchanged.
Incubation g shows a comparison of the digestion of an oligosaccharide 
Galp(l,4)Glc-p-0-0ctyl. After treatment with p-galactosidase (crude) galactose and 
glucose-octyl.
Incubation h shows no cleavage as expected between octyl lactoside and p- 
glucosidase. p-glucosidase can only cleave the glucose unit when the galactose is 
removed (some trace of p-galactosidase, present in p-glucosidase may hydrolyse).
Incubation j contains Glcp(l,6)Galp-0-0ctyl and p-galactosidase. As expected the 
major product is Glcp(l,6)Galp-0-0ctyl (unchanged).
Incubation k contains the following Neu5Aca(2,3)[Glcp(l,6)]Galp-0-0ctyl, C. 
perfringens neuraminidase and p-galactosidase. The neuraminidase has removed the 
sialic acid to give Glcp(l,6)Galp-0-0ctyl. This is the major product.
6.1.15 3 mg Preparative Scale Synthesis of
Neu5Aca(2,3)Galp(l,4)[pGal(l,6)]Glcp-0-0ctyI
Galp(l,4)[pGal(l,6)]Glcp-0-Octyl was first purified to one spot by T.L.C. on 
reverse-phase silica. The product was eluted in a gradient of 75 % MeOH.
3 mgs of Galp(l,4)[pGal(l,6)]Glcp-0-0ctyl were then incubated with 20 mgs of 
Neu5Ac-O-PNP. 4 mis of crude trans-sïaïiàsise (approximately 5 mgs/ml) was 
added and the reaction mixture was buffered with 2 mis HEPES (250 mM, pH 7.3). 
The incubation was heated to 37 and left for 16 hours. By T.L.C. two spots were 
present using CHCI3zMeOHiHiO (120:85:20).
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6.4.16 Incubation of Galp(l,4)[pGal(l,6)]Glcp-0-0ctyl
The T.L.C. plate clearly indicates two points of sialylation of
Galp(l,4)[pGal(l,6)]Glcp-0-0ctyl located with Rf s = 0.4, 0.2.
6.4.17 Purification of Neu5Aca(2,3)Galp(l,4)[pGai(l,6)]Glcp-0-0ctyl
The product was then isolated by chi’omatography (gravity) on reverse-phase silica. 
A gradient of 0-100% MeOH (In 25 % increments) was carried out. The product 
was isolated at 50 % MeOH. The product was then subject to further purification on 
A25 sephadex anion exchange resin. The sialylated product was eluted with 1 M 
NH4OAC. Approximately 1.0 mgs of sialylated material was isolated. The product 
was then characterised by electro spray-MS.
6.4.18 Analysis of Neu5Aca(2,3)Galp(l,4)[pGal(l,6)]Glcp-0-0ctyl 
Electrospray Mass Spectrometry
There are clearly two peaks as expected by T.L.C., these are located at 906.99 and
1197.16 Da/e, corresponding to the mono and di-sialylated
Galp(l ,4)[pGal(l ,6)]Glcp-0-0ctyl.
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6.5 Galp-SX analogue library radiochemical assay
The radiochemical assay was set up and carried out on compounds Al-JlO (twice), 
as before {Pereira et al 1995, Vetere et al 1996), see pages 48 and 111. Tables 28- 
37 show the total radioactive counts in each assay.
Table 28 Radioactive screen Al-AlO (All Numbers are in DPM)
Modified substrates Wash Elution Total E/Total %
Al 16900 13013 29913 44
A2 24233 6108 30342 20
A3 20285 8921 29206 31
A4 24082 6493 30575 21
A5 18791 11191 29982 37
A6 23314 6766 30080 22
A l 23124 6699 29823 22
A8 22817 6978 29795 23
A9 20503 9305 29808 31
AlO 20494 9262 29758 31
No substrate 16586 11637 28223 41
No enzyme 27931 1364 29295 5
Table 29 Radioactive screen Bl-BlO (All Numbers are in DPM)
Modified Substrates Wash Elution Total E/Total %
B1 23121 6261 29389 21
B2 18807 9170 27978 33
B3 17503 12650 30153 42
B4 20763 9027 29790 30
B5 22340 7583 29923 25
B6 21490 8462 29952 28
B7 0 0 0 0
B8 21124 8737 29860 29
B9 21454 7838 29292 27
BIO 18612 11329 29942 38
No substrate 16586 11637 28223 41
No enzyme 27931 1364 29295 5
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Table 30 Radioactive screen Cl-ClO (All Numbers are in DPM)
Modified Substrates Wash Elution Total E/Total %
Cl 22164 11638 33802 34
C2 21587 8153 29740 27
C3 18762 10202 28964 35
C4 0 0 0 0
C5 21186 8339 29525 28
C6 21309 7501 28810 26
Cl 21082 5512 26594 21
C8 24094 6077 30172 20
C9 0 0 0 0
CIO 22949 6455 29405 22
No substrate 16586 11637 28223 41
No enzyme 27931 1364 29295 5
Table 31 Radioactive screen Dl-DlO (All Numbers are in DPM)
Modified Substrates Wash Elution Total E/Total %
D1 23119 6567 29686 22
D2 22123 5616 27739 20
D3 17121 10903 28024 39
D4 23645 3847 27492 14
D5 24941 5176 30116 17
D6 19024 10560 29584 36
D7 0 0 0 0
D8 19381 8651 28033 31
D9 0 0 0 0
DIO 24094 6600 30694 22
No substrate 18717 11398 30115 38
No enzyme 29451 1462 30913 5
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Table 32 Radioactive screen El-ElO (All Numbers are in DPM)
Modified Substrates Wash Elution Total E/Total %
El 22236 6625 28861 23
E2 27784 5007 32791 15
E3 20382 8583 28965 30
E4 21403 8460 29863 28
E5 24802 5276 30078 18
E6 24277 6125 30401 20
E7 24231 6200 30431 20
E8 22223 8155 30378 27
E9 20511 6882 27393 25
ElO 20226 9331 29557 32
No substrate 18717 11398 30115 38
No enzyme 29451 1462 30913 5
Table 33 Radioactive screen Fl-FlO (All Numbers are in DPM)
Modified Substrates Wash Elution Total E/Total %
FI 24943 6840 31783 22
F2 24377 7330 31707 23
F3 23047 7858 30906 25
F4 19287 10791 30079 36
F5 25189 5528 30717 18
F6 20082 10820 30902 35
F7 20384 10658 31042 34
F8 22693 7754 30447 25
F9 23232 6646 29878 22
FIO 22437 7884 30321 26
No substrate 18717 11398 30115 38
No enzyme 29451 1462 30913 5
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Table 34 Radioactive screen Gl-GlO (All Numbers are in DPM)
Modified Substrates Wash Elution Total E/Total %
G1 25439 6751 32190 21
G2 18947 11782 30729 38
G3 0 0 0 0
G4 0 0 0 0
G5 25661 7286 32947 22
G6 23393 6182 29575 21
G7 22273 9815 32089 31
G8 20150 11980 32129 37
G9 21791 10907 32698 33
GIO 28211 7169 35380 20
No substrate 21725 10903 32628 34
No enzyme 34097 986 35083 3
Table 35 Radioactive screen H l-HlO (All Numbers are in DPM)
Modified Substrates Wash Elution Total E/Total %
HI 23342 7011 30354 23
H2 24400 6165 30565 20
H3 22364 8330 30694 27
H4 19778 10451 30229 35
H5 27410 3671 31082 12
H6 31073 5588 36661 15
H7 36849 5376 42225 13
H8 32476 9622 42098 23
H9 26938 10355 37293 28
HIO 36847 7073 43920 16
No substrate 21725 10903 32628 34
No enzyme 34097 986 35083 3
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Table 36 Radioactive screen Il-IlO (AU Numbers are in DPM)
Modified Substrates Wash Elution Total E/Total %
11 30844 9917 40761 24
12 31592 8569 40162 21
13 30009 8732 38741 23
14 24790 10831 35621 30
15 32522 7499 40021 19
16 38223 6350 44573 14
17 32843 6844 39687 17
18 29213 9724 38937 25
19 33018 6769 39779 17
110 32267 6405 38672 17
No substrate 27036 13023 40059 33
No enzyme 42846 1229 44075 3
Table 37 Radioactive screen J l-JlO  (AU Numbers are in DPM)
Modified Substrates Wash Elution Total E/Total %
J1 30237 8903 39140 23
J2 28205 10753 38959 28
J3 27973 8703 36676 24
J4 30637 8356 38993 21
J5 27423 10550 37972 28
J6 32352 4856 37207 13
J7 33195 6806 40001 17
J8 24948 9930 34878 28
J9 31996 6741 38738 17
JIO 30946 6294 37240 17
No substrate 27036 13023 40059 33
No enzyme 42846 1229 44075 3
Shown below in Figure 70 are the graphs of total counts of radioactivity, observed 
in screens Al-JlO inclusive.
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Figure 70 Total radioactive counts of Galp-SX analogue library
35000 
30000 
25000 
§■ 20000 
B  15000
I  10000
^  5000
0
35000 
30000 
5  25000
CL9 . 20000 
I  15000 
10000 
5000 
0
■  l l f i n i a lliNin'iiin
I 2 3 4  5 6 7 8 9 1 0  No  No
Al-10 Gaip-SXanalogues
fur II I  ■■■
9 10 No No
C 1-10 G a l p - S X  a n a l o g u e s
35000-,
30000
g 25000-%B 20000■a1 15000-H
10000
5000
1 2 3 4 s 6 7 8 9 10 No No
El-10 Galp -SX analogues
40000 -,
35000
30000
25000
20000 i fH 1500010000
5000
9 10 No  No
0 1 - 1 0  G a l p - S X  a n a l o g u e s
45000-,
40000
35000f.o 3000025000I 20000
H 15000
10000
5000
1 2 3 4 5 6 7 8 9  10 No  No
35000 
30000 
g  25000 
B  20000
I  15000 
10000 
5000 
0
lin in f in
1 2 3 4  5 6 7 8 9 1 0  No  No
B l -10  G a lp - S X  an a lo g u es
35000
30000
f  2 5 0 0 0  Sr£  20000 
g  15000 
10000 
5000 
0 m i l
Dl-lO Galp-SX analogue»
35000
30000
S  25000
20000
15000
0000
I 2 3 4 S  6 7 8 9 1 0  N o N o
Fl-10  G a lp -S X  an a lo g u es
45000 
40000 
35000 
f  30000 
B  25000
I  20000
^  15000
10000 
5000 
0
I i 'H  I
9 10 No No
H l - 1 0  G a lp - S X  a n a lo g u e s
45000
40000
35000
30000
25000
5  20000
15000
10000
11-10 Galp-SX analogues Jl-10 Galp-SX analogues
6.6 Best substrates from Galp-SX analogue radioactive screen
The best substrate of the radioactive screen encompassing compounds Al-JlO were 
selected and assayed again to ascertain the best substrate of the group. Table 38 
shows the result of this assay.
Table 38 Best substrates from Galp-SX analogue radioactive screen
Sample Wash Elution Total % E/Total
D4 40030 8848 48878 18
E2 37760 9500 47260 20
H5 38061 7786 45847 17
J6* 41491 5204 46695 11
Control 31369 15376 46745 33
No enzyme 44189 3399 47588 7
*Best substrate, use for serial dilution later
6.7 Serial dilution of Galp(l,4)[ pGal(l,6)]Glcp-Octyl (21) radioactive screen
As Galp(l,4)[pGal(l,6)]Glcp-Octyl (21) proved to be the best substrate of the 
Galp(l,X)gal assay, this compound was subject to a serial dilution to calculate IC50 
for this substrate. After dilution, the resultant concentrations were assessed 
radiochemically, as before, page 48 and 111. The total counts of this radioactive 
assay are shown below in Table 39.
Table 39 Serial dilution of Galp(l,4)[ pGal(l,6)]Glcp-Octyl radioactive 
screen (Serial Dilution)
Galp(l,4)[pGaI(l,6)]Glcp-Octyl
Concentration
Wash Elution Total % E/Total
1 mM 32729 7973 40254 2 0
0.5 mM 30618 11374 41993 27
0.25 mM 27552 10218 37770 27
0.1 mM 29784 11747 41531 28
0.05 mM 27295 13919 41214 34
No substrate 26402 14123 40525 35
No enzyme 37363 3894 41257 9
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6.8 Serial dilution of J6 (Galp-SX analogue) radioactive screen
Since J6 was determined as the best substrate of the radiochemical assessment of the 
Galp-S-X analogues, a serial dilution was carried out on this compounds and the 
resultant concentrations assessed radiochemically. The total counts of this 
radioactive assay are shown below in Table 40.
Table 40 Serial dilution of J6 (Galp-SX analogue) radioactive screen
J6 (Galp-SX analogue) 
concentration
Wash Elution Total % E/Total
1 mM 32188 9350 41538 23
0.5 mM 30599 11919 42518 28
0.25 mM 27187 11397 38583 30
0.1 mM 26431 14907 41337 36
0.05 mM 26900 14026 40926 34
No substrate 26402 14123 40525 35
No enzyme 37363 3894 41257 9
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Chapter 7
Conclusions and Further
work
135
7.1 frawy-Sialidase isolation and purification
Recombinant Trypanosoma cruzi /raw^-sialidase over-expressed in E. coU was 
grown in media and the protein isolated. It was purified by anion exchange and 
affinity chiomatography to the level of a single band on a silver stained SDS gel(see 
appendix 1).
7.2 /ra/i5-Sialidase assay development
A rapid reliable spectrophotometric coupled assay has also been developed for the 
purpose of measuring the activity of /ra«5'-sialidase during purification. This assay 
analyses both the hydrolysis and transferase activities of A'a^a'-sialidase. Using this 
assay it is possible to conclude that ^raws'-sialidase is preferentially a transferase.
7.3 Radioactive screening of traffs-sialidase potential substrates
Studies have been carried out on three mutually exclusive sets of synthetic 
saccharide derivatives to map substmte recognition by the enzyme. Synthetic 
fragments of the natural branched oligosaccharide substrates have also been 
incorporated into these studies.
7.4 Screening of Galp-O-Octyl and GalpGlcNAcp-O-Octyl analogues
The radiochemical assessment of Galp-O-Octyl analogues and GalpGlcNAcp-O- 
Octyl analogues indicate that modification of the hydroxyl groups at positions 2 and 
4 on the terminal galactose results in minimum turnover only. Also modification of 
the hydroxyl gioup at position 3 rendered the substrate unsialylable (as expected). 
However the hydroxyl group at position 6 seems to be unimportant for sialylation 
and may be modified extensively.
The hydi'oxyl groups of the internal sugar (of disaccharide) may also be 
altered in many ways, the presence of the second sugar unit seeming to increase the 
substrate efficacy. These points are summarised in Figure 71 below.
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Figure 71 Modifications to saccharides which influence trans-sialidase sialyl 
transfer
Minimal turnover
9*1^  Bulk OH
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OHOH
N o turnover
Minimal turnover
Radiochemical assay results using fragments of the natural substrates have also 
given interesting findings. It has been possible to sialylate Glcp(l,6)Galp-0-0ctyl. 
This is important since it has been well documented in the literature that is has only 
been possible to sialylate terminal galactose residues {Schenkman and 
Vandekerckhove 1992). Our conclusions have not fully indicated where tram- 
sialidase has attached the sialic acid, but have conclusively shown that the substrate 
has been sialylated. (See mass spectrum. Figure 56, page 75). It is highly likely 
that the sialic acid has been attached to the internal galactose, since all prior studies 
have shown glucose to be a non-substrate. This does, however, indicate that the 
active site of trans-sialidasQ has the capacity to hold another monosaccharide at the 
six position of galactose (as well as an anomeric octyl chain). Figure 72A shows a 
possible general model of the /raw-sialidase active site with the orientation of the 
substrate, Galp(l,6)X.
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Figure 72A /ra/t5-sialidase binding site showing the possible orientation of the 
substrate Galp(l,6)X
The hydroxyl shown in red is the point of attachment of sialic acid. This model of 
trans-siddxdasQ is supported by the confirmation of the di-sialylation of 
Galp(l,4)[pGal(l,6)]GlcNAcp-0-0ctyl (see mass spectrum, Figure 61, page 81). 
This result suggests that it is possible to sialylate an internal galactose.
7.5 Chemo-enzymatic synthesis
Galp(l,4)[pGal(l,6)]GlcNAcp-0-0ctyl, Glcp(l,6)Galp-0-0ctyl and Galp(l,6)Galp- 
0-CH2-CH2-Si(CH3)3 were sialylated using /ra/75'-sialidase preparatively, indicating 
the potential of trans-sialidasQ for chemo-enzymatic synthesis. Each of these 
compounds were isolated and their structures confirmed by mass spectrometry. 
Galp(l,4)[pGal(l,6)]GlcNAcp-0-0ctyl and Glcp(l,6)Galp-0-0ctyl were also subject 
to enzymatic digestion.
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7.6 Further work |
I
^#Yi«5-sialidase in organic synthesis
Sialylation of trisaccharides such as Glcp(l,X)Glcp(l,6)Galp-0-0ctyl or R- 
Galp(l,X)Galp-0-0ctyl (where X = any linkage and R = any other large moiety) 
should give more information about the size of the active site of Zraw-sialidase and 
exploit further the a(2,3) sialyl acid transfer potential use of this enzyme in 
carbohydrate synthesis. j
Inhibitor development
!
Development of inhibitors to /row^'-sialidase could use an -S- linked donor substrate, 1
i.e. Neu5Ac-a(2,3)-S-Gal or analogues of this general structure, shown below in |
Figure 72B.
Figure 72B Neu5Ac-a(2,3)-S-Gal !
oHO OH
OH
HO OH
Neu5Ac-a(2,3)-S-Gal
This structure should be likely to act as a Neu5Ac donor for /raw^-sialidase since it 
incorporates the Neu5Ac-S-Gal bond, which should be less susceptible to sialyl 
transferase.
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Appendix 1
Al /ra/i5-Sialidase purification
Purification has encompassed two (and in some cases three) purification steps. We 
have successfully achieved a very high level of purity, with an equally high level of 
activity. The biggest problem has been a lack of material.
Our first purification protocol was modified to incorporate NP^-NTA resin 
{Hochuli et al 1987) as an initial column purification step. This column was 
adapted for the HPLC system. This was successful in increasing the level of purity 
of the material and speed. This has been confirmed, giving a single band on an SDS- 
Page silver stained gel at 69 kDa, Figure 73.
Figure 73 SDS-Gel of purified rra/fx-sialidase
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The first nickel step provides such a good separation, as it is based on the chelation 
of two histidine residues (attached to the protein) with nickel cations immobilised in 
the resin. This column is eluted with imidazole.
Material that was recovered from this nickel purification step was first 
dialysed into tris (50 mM), pH 8, (to get rid of the imidazole) and concentrated on a 
50 kDa cut off filter, before being loaded on to an anion exchange (HQ) column.
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This column employs a salt gradient to elute the protein. As this is a high-velocity 
column, it gives a very fast separation, as illustrated below in Table 41.
Table 41 Average protein purification table
Purification Step Protein Cone. A400 nm (10 Mins)
1. Initial lysis 64.0 mgs .1
2. Ni-NTA HPLC (Fraction 1) 10.2 mgs .12
3. Ni-NTA HPLC (Fraction 2) 4.8 mgs .09*
4. Centricon 50 5.8 mgs .12
5. HQ 208 HPLC (Fraction 1) 120 figs .15
6. HQ 208 HPLC (Fraction 2) 180 figs .09
*This fraction was not purified any ;firther.
A1.2 Protein purification protocol - small culture preparation
A single bacterial colony was removed from an agar plate and transferred into sterile 
LB broth, inoculated with ampicillin (100 gg/ml) and kanamycin monosulphate (25 
gg/ml). The culture was then grown in an incubator at 37 “C with gentle agitation 
(150 RPM), until it reached an optical density of 0.6. This culture was then 
transferred into 6x 2 L shake flasks, containing LB Miller broth (500 mis,sterile) and 
inoculated with ampicillin and kanamycin monosulphate as before. The bacteria was 
grown at 37 ^C, with agitation of 175 RPM again until it reached an OD of 0.6. At 
this point the culture was induced with IPTG (1 mM), the temperature reduced to 25 
and the agitation reduced to 150 RPM. The cells were left in the incubator for 16 
hours approximately. The broth was spun down at 6198 g  (6,000 RPM), 4 ^C, for 20 
mins and the pellets collected.
A1.3 Cell Lysis
The wet cells were removed and the weight recorded before being re-suspended in 
50 mM sodium phosphate, 300 mM NaCl, and 50 mM imidazole buffer pH 8 
(sonication buffer). Lysozyme (1 mg/ml) and ETDA (2 mM) was added and the 
solution which was left to stir at 4 ”C for 30 mins. The cells were then sonicated (6x 
30 second bursts). DNase 1 (5 gg/ml) was added to the solution which was allowed 
to stir for a further 15 mins at 4 ®C. After this time, the material was spun down at
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27167 g (15,000 RPM), 4 ®C for 20 mins. The supernatant was removed and the 
volume recorded.
A1.4 Ni^ -^NTA column purification
Nf"*" NT A beads were added to the culture (1 mis per 1 L, previously adjusted to pH 
8). The beads were then washed with 4x bead volumes of lysis buffer (sodium 
phosphate (50 mM), NaCl (350 mM), and imidazole (20 mM), pH 8.1) to remove the 
storage material. The protein was added to the beads and shaken. This was left for 1 
hour before being drained off and tested for activity. As the supernatant was no 
longer active, it was assumed that /‘raw^'-sialidase had bound to the resin. The resin 
was then washed with buffer (sodium phosphate(50 mM), and NaCl (350 mM), pH 
8.1). This process used lOx bead volume and it was repeated 4x. The washes were 
checked by uv spectrophotometry. When there was no further imidazole reading, the 
beads were eluted with buffer containing sodium phosphate (50 mM), NaCl (100 
mM), and imidazole (800 mM), pH 8.1. This used Ix bead volume and was repeated 
3x. The protein was assayed for activity and Bradford reagent used to establish the 
protein concentration, {Scopes 1994). The protein was dialysed immediately to 
remove the imidazole.
Al.4.2 Ni^  ^NTA column purification (HPLC)
Ni^^ NTA beads were packed into a column that has been adapted to fit the HPLC 
system. It was first equilibrated with 2 column volumes of wash buffer, sodium 
phosphate (50 mM), NaCl (300 mM), pH 8. The protein was loaded on, washed and 
then eluted with sodium phosphate (50 mM), NaCl (100 mM) and imidazole (500 
mM) buffer pH 8. The protein was collected and dialysed immediately.
A1.5 Anion exchange chromatography
The protein was loaded onto the column with a flow rate of about 6 CV per min. 
The buffer used was trisma (50 mM) pH 8 and NaCl (4 M). A salt gradient was 
conducted jftom 0 to 4000 mM. The protein eluted at approximately NaCl (200 
mM) assayed for activity and protein concentration.
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Appendix 2
A2 Kinetic properties of many enzymes
In general the catalysis rate, v, of an enzyme is dependant on the concentration of the 
substrate [S], present, where V is the number of moles of product formed per second. 
V is directly proportional to [S], when [S] is small, with a fixed amount of enzyme, 
but at a high [S], v is almost independent of [S]. These properties are accounted for 
by the Michaelis-menten model. The simplest expression that accounts for enzyme 
kinetics is as follows -
E + S ES E + P
Where E = Enzyme, S = Substrate, ES = Enzyme substrate complex, P == Product
and kR are rate constants. It is assumed that at the initial stage of the 
reaction, i.e. when the concentration of the product is low, that none of the product 
reverts to the substrate. The rate of production of product at this stage is governed 
by ks. This is shown in Figure 74, below.
Figure 74 Reaction velocity as a function of substrate concentration
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Substrate Concentration [S]
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The expression is -
v = ^i[ES]
We can express [ES] in known terms -
Rate of formation of ES = A:/[E][S]
And the Rate of breakdown of ES = (A2+ ^^)[ES]
In a steady state, the concentration of reactants and products are changing, but the 
concentrations of the intermediates is the same i.e.
kj[E][S] = {k2^k3)\ES]
by rearrangement [ES] = [E][S]
(k2+ ks)/ k]
Or by defining Km, the Michaelis-Menten constant
Km = k2+k3 = [E][S]
ki [ES]
The assumption is that the substrate concentration is significantly greater than the 
enzyme concentration, and that the concentration of enzyme is given by
[E] =[E t]-[E S ]
Wliere Ex is the total enzyme concentration present. So by substitution of [E] gives
Æm = ([Ex]-[ES])[S]
[ES]
Solving with respect to [ES] gives
[ES]=k3[Ex][S]
Æm+[S]
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Since Emax = kg [E t ] by substitution it is possible to obtain the following Michaelis- 
Menten equation:
[S]
V = E max [S]+Km
When [S] = Æm, and v = Emax i.e. Km is equal to the substrate concentration at 
wliich the reaction rate is half of its maximal value.
The Michaelas-Menten expression can be derived by measuring the rate of reaction 
with a variety of substrate concentrations, this can be transfonned by a double 
reciprocal plot to give a straight line, i.e. a Lineweaver-Burk plot.
Lineweaver-Burk Equation :
1 1 Km
—  +  _________
1
V Emax Emax S
This is shown below diagrammatically in Figure 75 
Figure 75 Lineweaver -  Burk Plot
Intercept = -HKm
Intercept = 1/Emax
Slope = AW Emax
1/[S]
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A2.2 Significance of Am and Fmax values
The Am of an enzyme usually lies between 10'^  and 10'^  M and can vary depending 
on conditions, substrates, ionic strength, pH and temperature. The Am is an 
indication of the substrate concentration at which half of the active sites are filled. 
But since
Am = k2 + kg
This also gives an indication of the relative rates of reaction compared to each other.
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